<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/252371-indozolone-derivatives-as-11b-hsd-1-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:24:01 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 252371:INDOZOLONE DERIVATIVES AS 11B-HSD 1 INHIBITORS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">INDOZOLONE DERIVATIVES AS 11B-HSD 1 INHIBITORS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>This invention is concerned with compounds of the formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R7 have the significances given in the description and claims can be used in the form of pharmaceutical compositions.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The present invention is concerned with novel indazolone derivatives which are useful as 11b-HSDl inhibitors.<br>
The invention is concerned particularly with compounds of formula (I)<br>
(Formula Removed)<br>
wherein:<br>
R1 is hydrogen, C1-C7-alkyl, aryl, or aryl-C1-C7-alkyl;<br>
R2 is aryl, aryl-C1-C7-alkyl, heteroaryl, heteroaryl-C1-C7-alkyl, cycloalkyl, cycloalkyl-<br>
C1-C7-alkyl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is optionally<br>
substituted with 1 to 3 substituents selected from the group consisting of OH, CN,<br>
halogen, C1-C7-alkoxy and C(O)NR8R9;<br>
R3 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R4 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R5 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R6 is hydrogen or C1-C7-alkyl;<br>
R7 is aryl, heteroaryl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is<br>
optionally substituted with 1 to 3 substituents selected from the group consisting of OH,<br>
CN, halogen, C1-C7-alkoxy and cycloalkyl;<br><br>
R8 and R9, independently from each other, are selected from the group consisting of hydrogen and C1-C7-alkyl; and pharmaceutically acceptable salts thereof.<br>
Glucocorticoids (Cortisol in humans, corticosterone in mice and rats) are an important class of adrenocorticosteroids that regulate many metabolic and homeostatic processes and form a key component of the response to stress. Glucocorticoids act via intracellular glucocorticoid receptors and, in some tissues, mineralocorticoid receptors; both being nuclear transcription factors. Glucocorticoid action on target tissues depends not only on circulating steroid concentrations and the cellular expression of receptors, but also on intracellular enzymes that critically determine to which extent glucocorticoids gain access to receptors in an active form. 1 lbeta-hydroxysteroid dehydrogenases (1 lbeta-HSD's) catalyze the interconversion of the principal active 11-hydroxy-glucocorticoid (Cortisol in men) and their inactive 11-keto metabolites (cortisone in men).<br>
The enzyme 1 lbeta-hydroxysteroid dehydrogenase type 1 (1 lbeta-HSDl) inter-converts inactive into active glucocorticoids, thereby playing a major role in local modulation of cellular agonist concentration and thus activation of corticosteroid receptors in target tissues. In a recent study made by F. Hoffmann-La Roche differences in gene expression in lean and obese men were analyzed using gene array technology in order to identify specific changes in gene expression that might be associated with insulin resistance or altered metabolism. This study revealed that the mRNA for 1 lbeta-HSDl is approximately two-fold up regulated in adipose tissue in obese individuals. Moreover, overexpressing 1 lbeta-HSDl in adipocytes of mice led to visceral obesity and to a syndrome-X like phenotype (Masuzaki H. et al., Science. 2001 Dec 7; 294(5549):2166-70.). Taken together, these data very strongly support an important role of 1 lbeta-HSDl in the induction of obesity and the impairment of glucose homeostasis and lipid parameters. Thus, selective inhibition of this enzyme could lower blood glucose levels in Type 2 diabetic patients, normalize elevated lipid parameters and/or reduce weight in obese subjects.<br>
The first pharmacological indication that 1 lbeta-HSDl inhibition in men might have beneficial effects were obtained by using carbenoxolone, an anti-ulcer drug<br>
which inhibits both llbeta-HSDl and the related enzyme llbeta-HSD2. Treatment<br>
with carbenoxolone led to an increase in insulin sensitivity indicating that that<br>
inhibition of llbeta-HSDl may reduce cellular cortisol levels and therefore<br>
minimizing some of its deleterious effects. (Walker et al. 1995; J. Clin. Endocrinol.<br>
Metab. 80,31155-3159).<br>
llbeta-HSDl is expressed in many tissues including liver, adipose tissue,<br>
vascular smooth muscles, pancreas and brain. Its activity is dependent on NADP(H)<br>
and it has a relatively low affmity for its substrate (compared to llbeta-HSD2). 11<br>
beta-HSDl in tissue homogenates and when purified is bidirecţional, exhibiting both<br>
llbeta-dehydrogenase and l Ibeta-reductase reactions, with greater stability of the<br>
dehydrogenase activity (P.M. Stewart and Z.S. Krozowski, Vitam. Horm. 57 (1999),<br>
pp. 249-324). However, when the enzyme activity is tested in intact cells, the l Ibetareductase<br>
activity predominates, which regenerates active glucocorticoids from inert<br>
11-keto forms. Such glucocorticoid regeneration will increase effective intracellular<br>
glucocorticoid levels and thereby amplifying glucocorticoid activity. It is this elevated<br>
cellular cortisol concentration that might lead to increased hepatic glucose production,<br>
adipocyte differentiation and insulin resistance.<br>
Inhibition of llbeta-HSDl should not only reduce the typical Syndrome-X /<br>
Diabetes associated symptoms, but it should also be save and without major side<br>
effect. Studies with the unspecific inhibitor carbenoxolone highlight the importance of<br>
developing specific llbeta-HSDl inhibitors. The inhibition of the llbeta-HSD2<br>
enzyme is badly tolerated and results in increased blood pressure. In contrast<br>
inhibition of llbeta-HSDl should be well tolerated since llbeta-HSDl knockout<br>
mice were found be healthy and to resist hyperglycemia provoked by obesity or stress<br>
(Kotelevtsev Y. et al., Proc Natl Acad Sci U S A . 1997 Dec 23;94(26):14924-9).<br>
Similar upon starvation these mice hâd attenuated activation of key hepatic enzymes<br>
that are involved in gluconeogenesis. In addition, these mice hâd improved lipid and<br>
lipoprotein profiles suggesting that inhibition of HSD1 might be highly efficacious<br>
and safe. Recent reports indicate that llbeta-HSDl inhibitors might also be beneficial<br>
to reduce high blood pressure (Masuzaki H. et al., J Clin Invest. 2003 July;l 12(1):83-<br>
90; Rauz S. et al., QJM. 2003 July;96(7):481-90) to improve cognition (Sandeep TC.<br>
et al., Proc Natl Acad Sci U S A . 2004 Apr. 27;101(17):6734-9) or to improve<br>
Alzheimer associated deficits. Taken together llbeta-HSDl inhibition might be a<br>
save and efficacious approach to treat symptoms of diabetes, obesity and other<br>
diseases.<br>
The compounds of formula I and their pharmaceutically acceptable salts and<br>
esters are novei and have valuable pharmacological properties. In particular they are<br>
llb-HSDl inhibitors and they display selectivity against the related llbeta-HSD2<br>
enzyme. Therefore the compounds which are specific llbeta-HSDl inhibitors<br>
represent an approach to e.g. lower blood glucose levels and normalize lipid<br>
parameters in Type 2 diabetic patients by modulating the local concentratiqn of the<br>
active glucocorticoid cortisol in target tissue (liver, adipose tissue).<br>
The compounds of the present invention can be used in the prophylaxis and/or<br>
treatment of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes,<br>
particularly diabetes Type II. The compounds of this invention can further be used in<br>
the prophylaxis and/or treatment of high ocular eye pressure, cognition, Alzheimer<br>
and/or neurodegeneration.<br>
Objects of the present invention are the compounds of formula I and their<br>
aforementioned salts per se and their use as therapeutically active substances, a<br>
process for the manufacture of the said compounds, intermediates, pharmaceutical<br>
compositions, medicaments containing the said compounds, their pharmaceutically<br>
acceptable salts, the use of the said compounds and salts for the prophylaxis and/or<br>
therapy of illnesses, especially in the treatment or prophylaxis of metabolic disorders,<br>
obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II, and<br>
the use of the said compounds and salts for the production of medicaments for the<br>
treatment or prophylaxis of metabolic disorders, obesity, dyslipidemiae, hypertension<br>
and/or diabetes, particularly diabetes Type II.<br>
The compounds of the present invention can further be combined with PPAR<br>
(alpha, gamma, delta) agonists, DHEA (dehydroepiandrosterone), DPPIV inhibitors,<br>
insulin and/or lipase inhibitors, particularly orlistat.<br>
Unless otherwise indicated, the following defmitions are set forth to illustrate<br>
and defme the meaning and scope of the various terms used to describe the invention<br>
herein.<br>
In this specification the term "lower" is used to mean a group consisting of one<br>
to seven, preferably of one to four carbon atom(s).<br>
The term "halogen" refers to fluorine, chlorine, bromine and iodine, with<br>
fluorine, chlorine and bromine being preferred.<br>
The term "alkyl", alone or in combination with other groups, refers to a<br>
branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one<br>
to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one<br>
to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl<br>
groups.<br>
The term "lower-alkyl", alone or in combination with other groups, refers to a<br>
branched or straight-chain monovalent alkyl radical of one to seven carbon atoms,<br>
preferably one to four carbon atoms. This term is fiirther exemplified by such radicals<br>
as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like. Lower-alkyl<br>
groups can optionally be substituted, e.g. by OH, CN, halogen, lower-alkoxy, or<br>
aminocarbonyl. Unsubstituted lower-alkyl groups are preferred.<br>
The term "fluoro-lower-alkyl" refers to lower-alkyl groups which are mono- or<br>
multiply substituted with fluorine. Examples of fluoro-lower-alkyl groups are e.g.<br>
CFH2, CF2H, CF3, CF3CH2, CF3(CH2)2, (CF3)2CH and CF2H-CF2<br>
The term "cycloalkyl" refers to a monovalent carbocyclic radical of 3 to 10<br>
carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl,<br>
cyclopentyl, or cyclohexyl.<br>
The term "alkoxy" refers to the group R'-O-, wherein R' is an alkyl. The term<br>
"lower-alkoxy" refers to the group R'-O-, wherein R' is a lower-alkyl.<br>
The term "fluoro-lower-alkoxy" refers to the group R"-O-, wherein R" is<br>
fluoro-lower-alkyl. Examples of fluoro-lower-alkoxy groups are e.g. CFH2-0, CF2HO,<br>
CF3-O, CF3CH2-O, CF3(CH2)2-O, (CF3)2CH-O, and CF2H-CF2-O.<br>
The term "amino", alone or in combination, signifies a primary, secondary or<br>
tertiary amino group bonded via the nitrogen atom, with the secondary amino group<br>
carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two<br>
similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents<br>
together forming a ring, such as, for example, -NHj, methylamino, ethylamino,<br>
dimeţhylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc.,<br>
preferably primary amino, dimeţhylamino and diethylamino and particularly<br>
dimeţhylamino.<br>
The term "alkylene" refers to a straight chain or branched divalent saturated<br>
aliphatic hydrocarbon group of l to 20 carbon atoms, preferably l to 16 carbon atoms,<br>
more preferably up to 10 carbon atoms. Lower-alkylene groups as described below<br>
also are preferred alkylene groups. The term "lower-alkylene" refers to a straight chain<br>
or branched divalent saturated aliphatic hydrocarbon group of l to 7, preferably l to 6<br>
or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.<br>
The term "aryl", alone or in combination, relates to the phenyl or naphthyl<br>
group, preferably the phenyl group, which can optionally be substituted by l to 5 ,<br>
preferably l to 3, substituents independently selected from the group consisting of<br>
lower-alkyl, lower-alkoxy, halogen, hydroxy, CN, CFs, amino, aminocarbonyl,<br>
carboxy, NOa, dioxo-lower-alkylene (forming e.g. a benzodioxyl group), loweralkylsufonyl,<br>
aminosulfonyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, loweralkylcarbonyl-<br>
NH, lower-alkoxycarbonyl, fluoro-lower-alkyl, fluoro-lower-alkoxy,<br>
cycloalkyl, phenyloxy and methyl-oxadiazolyl. Preferred substituents are halogen,<br>
lower-alkyl, fluoro-lower-alkyl and CN.<br>
The term "heteroaryl" refers to an aromatic 5 to 6 membered monocyclic ring or<br>
9 to 10 membered bicyclic ring which can comprise l, 2 or 3 atoms selected from<br>
nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, oxo-pyridazinyl,<br>
pyrimidinyl, 2-oxo-pyridinyl, 2-oxo-pyrimidinyl pyrazinyl, thienyl, isoxazolyl,<br>
oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl,<br>
isothiazolyl, 1,2,3-thiadiazolyl, benzoimidazolyl, indolyl, indazolyl. A preferred<br>
heteroaryl group is pyridinyl. A heteroaryl group may have a substitution pattern as<br>
described earlier in connection with the term "aryl".<br>
Compounds of formula (I) can form pharmaceutically acceptable acid addition<br>
salts, Examples of such pharmaceutically acceptable salts are salts of compounds of<br>
formula (I) with physiologically compatible mineral acids, such as hydrochloric acid,<br>
sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as<br>
methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid,<br>
trifluoroacetic acid, citric acid, fumărie acid, maleic acid, tartaric acid, succinic acid or<br>
7<br>
salicylic acid. The term "pharmaceutically acceptable salts" refers to such salts.<br>
Compounds of formula (I) in which a COOH group is present can further form salts<br>
with bases. Examples of such salts are alkaline, earth-alkaline and ammonium salts<br>
such as e.g. Na-, K-, Ca- and Trimethylammoniumsalt. The term "pharmaceutically<br>
acceptable salts" also refers to such salts. Salts obtained by the addition of an acid are<br>
preferred.<br>
The compounds of formula I can also be solvated, e.g. hydrated. The solvation<br>
can be effected in the course of the manufacturing process or can take place e.g. as a<br>
consequence of hygroscopic properties of an initially anhydrous compound of formula<br>
I (hydration). The term pharmaceutically acceptable salts also includes physiologically<br>
acceptable solvates.<br>
In detail, the present invention relates to compounds of formula (I)<br>
(Figure Remove)wherein<br>
R1 is hydrogen, lower-alkyl, aryl, or aryl-lower-alkyl;<br>
R2 is aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, cycloalkyl,<br>
cycloalkyl-lower-alkyl, fluoro-lower-alkyl, or lower-alkyl, which lower-alkyl is<br>
optionally substituted with l to 3 substituents selected from the group consisting<br>
of OH, CN, halogen, lower-alkoxy and C(O)NR8R9;<br>
R3 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R4 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R5 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R6 is hydrogen or lower-alkyl;<br>
R7 is aryl, heteroaryl, fluoro-lower-alkyl, or lower-alkyl, which lower-alkyl is<br>
optionally substituted with l to 3 substituents selected from the group consisting<br>
of OH, CN, halogen, lower-alkoxy and cycloalkyl;<br>
R8 and R9, independently from each other, are selected from the group consiting of<br>
hydrogen and lower-alkyl;<br>
and pharmaceutically acceptable salts thereof.<br>
The compounds of formula I can have one or more asymmetric centers and can<br>
be present in the form of optically pure enantiomers, mixtures of enantiomers such as,<br>
for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers,<br>
diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The<br>
invention embraces all of these forms. Preferred are the compounds of formula I.<br>
Preferred compounds of formula (I) as described above are those wherein<br>
R1 is hydrogen, lower-alkyl, aryl, or aryl-lower-alkyl;<br>
R2 is aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, cycloalkyl,<br>
cycloalkyl-lower-alkyl, fluoro-lower-alkyl, or lower-alkyl, which lower-alkyl is<br>
optionally substituted with l to 3 substituents selected from the group consisting<br>
of OH, CN, halogen, lower-alkoxy and C(O)NR8R9;<br>
R3 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R4 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R5 is hydrogen, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, or fluorolower-<br>
alkoxy;<br>
R6 is hydrogen or lower-alkyl;<br>
R7 is aryl, heteroaryl, fluoro-lower-alkyl, or lower-alkyl, which lower-alkyl is<br>
optionally substituted with l to 3 substituents selected from the group consisting<br>
of OH, CN, halogen and lower-alkoxy;<br>
R8 and R9, independently from each other, are selected from the group consiting of<br>
hydrogen and lower-alkyl;<br>
and pharmaceutically acceptable salts thereof.<br>
A preferred embodiment of the present invention relates to compounds of<br>
formula (I) as described above, wherein R1 is hydrogen or lower-alkyl, preferably<br>
wherein R1 is hydrogen.<br>
Another preferred object of the present invention are the compounds of formula<br>
(I), wherein R2 is aryl-lower-alkyl, heteroaryl-lower-alkyl, cycloalkyl-lower-alkyl,<br>
fluoro-lower-alkyl, or lower-alkyl, which lower-alkyl is optionally substituted with l<br>
to 3 substituents selected from the group consisting of OH, CN, halogen, lower-alkoxy<br>
and C(O)NR8R9, wherein R8 and R9 are as defined above. Preferably, R2 is aryl-loweralkyl<br>
or heteroaryl-lower-alkyl, more preferably R2 is benzyl or pyridinylmethyl,<br>
wherein benzyl can optionally be substituted with l or 2 halogen. Especially preferred<br>
are those compounds wherein R2 is benzyl, 4-fluoro-benzyl, 4-chloro-benzyl, 3,4-<br>
difluoro-benzyl, or pyridin-2-ylmethyl. Other preferred compounds are those, wherein<br>
R2 is aryl, particularly phenyl.<br>
Also preferred are the compounds of formula (I), wherein R3 is hydrogen.<br>
Further preferred are those compounds according to formula (I), wherein R4 is<br>
hydrogen or halogen, particularly wherein R4 is hydrogen, fluorine, or chlorine.<br>
Another preferred aspect of the present invention are compounds of formula (I),<br>
wherein R5 is hydrogen or halogen, particularly wherein R5 is hydrogen. Other<br>
preferred compounds of formula (I) as defined above are those wherein R6 is<br>
hydrogen.<br>
In a further preferred embodiment of the present invention, R7 is lower-alkyl or<br>
aryl. Particularly preferred are those compounds, wherein R7 is lower-alkyl, phenyl or<br>
naphthyl, wherein phenyl can optionally be substituted with l to 3 substituents<br>
independently selected from the group consisting of lower-alkyl, fluoro-lower-alkyl,<br>
lower-alkoxy, fluoro-lower-alkoxy, dioxo-lower-alkylene, halogen, cyano, phenoxy<br>
and 5-methyl-[l,3,4]-oxadiazol-2-yl. More preferably, R7 is phenyl substituted with l<br>
to 2 substituents selected from the group consisting of lower-alkyl, fluoro-lower-alkyl,<br>
halogen and cyano, particularly 3-chloro-2-methyl-phenyl, 2,3-dichloro-phenyl, 3-<br>
chloro-4-fluoro-phenyl, 3-trifluoromethyl-4-fluoro-phenyl, 3-cyano-phenyl, 2,5-<br>
difluoro-phenyl, 3-chloro-2-fluoro-phenyl, 5-chloro-2-fluoro-phenyl, or 2-chlorophenyl.<br>
Other preferred compounds of formula (I) as described above are those,<br>
wherein R7 is fluoro-lower-alkyl or lower-alkyl substituted with cyclopropyl,<br>
especially those wherein R7 is cyclopropyl-methyl.<br>
Examples of preferred compounds of formula (I) are those selected from the<br>
group consisting of:<br>
N-( l -Benzyl-3 -oxo-2,3 -dihydro-1 H-indazol-5 -yl)-3 -chloro-2-methylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-fluorobenzenesu<br>
Ifonam ide,<br>
N-( l -Benzyl-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide,<br>
N-(lBenzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-benzenesulfonamide,<br>
Naphthalene-2-sulfonic acid (l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-methylbenzenesulfonamide,<br>
N-( l rBenzyl-3 -oxo-2,3-dihydro-1 H-indazol-5 -yl)-4-methoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-6-methylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-difluoro-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-propyl-benzenesulfonamide,<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonic acid (l-benzyl-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl)-amide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-2,5-dimethylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-3-trifluoromethylbenzenesulfonamide,<br>
-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chloro-5-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-phenoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-(5-methyl-[l,3,4]oxadiazol-2-yl)-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-methoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-difluoromethoxybenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3,5-bis-trifluoromethylbenzenesulfonamide,<br>
Propane-2-sulfonic acid (l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
N-(UBenzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-N-dimethylbenzenesulfonamide,<br>
N-(3-Oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide,<br>
2,3-Dichloro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-4-fluoro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
3-Chloro-2-methyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
3-Chloro-4-methyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
4-Chloro-2,5-dimethyl-N-(3-oxo-1 -phenethyl-2,3-dihydro-1 H-indazol-5-yl)-<br>
benzenesulfonamide,<br>
N-(3-Oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonatnide,<br>
N-( l LIsobutyl-3 -oxo-2,3-dihydro-1 H-indazol-5 -yl)-3 -trifluoromethylbenzenesulfonamide,<br>
3-Chloro-N-( l -isobutyl-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-4-methyl-<br>
12<br>
benzenesulfonamide,<br>
3-Chloro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-methylbenzenesulfonamide,<br>
3-Cyâno-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
3-Difluoromethoxy-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
4-Cyano-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
4-Fluoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide,<br>
3-Chloro-4-fluoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
2,4-Dichloro-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-5-methylbenzenesulfonamide,<br>
3-Chloro-N-(l-ethyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-methylbenzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-2-methylbenzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluorobenzenesulfonamide,<br>
(l-Cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluoro-3-trifluoromethylbenzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
2,4-Dichloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-5-methylbenzenesulfonamide,<br>
3-Chloro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
4-Fluoro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-3-trifluoromethylbenzenesulfonamide,<br>
3-Chloro-4-fluoro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide,<br>
2,4-Dichloro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-6-methylbenzenesulfonamide,<br>
3-Chloro-2-methyl-N-[3-oxo-l-(2,2,2-trifluoro-ethyl)-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesu Ifonam ide,<br>
4-Fluoro-[3-oxo-l-(2,2,2-trifluoro-ethyl)-2,3-dihydro-indazol-5-yl]-3-trifluoromethylbenzenesulfonamide,<br>
4-Fluoro-N-(3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
2,4-Dichloro-6-methyl-N-(3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
3-Chloro-2-methyl-N-(3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
4-Fluoro-N-[l-(2-hydroxy-2-methyl-propyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-fluorobenzenesu<br>
Ifonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichlorobenzenesulfonamide,<br>
N-(UBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-cyanobenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chlorobenzenesulfonamide,<br>
N-(UBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-difluoromethoxybenzenesulfonamide,<br>
N-( l rBenzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-2-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethoxybenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,5-difluoro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichlorobenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluorobenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-5-chloro-2-fluorobenzenesulfonamide,<br>
N-( l -Benzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-2-chlorobenzenesulfonamide,<br>
(l-Benzyl-4-chloro-3-oxo-2,3-dihydro-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide,<br>
N-(lBenzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethylbenzenesu<br>
Ifonam ide,<br>
N-( l -Benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-2,3-dichlorobenzenesulfonamide,<br>
N-( l -Benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-2,4-dichlorobenzenesu<br>
Ifonamide,<br>
N-(lfBenzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluorobenzenesu<br>
Ifonamide,<br>
N-(l"Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-5-chloro-2-fluorobenzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethoxybenzenesulfonamide,<br>
3-Chloro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesu Ifonamide,<br>
3-Difluoromethoxy-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
4-Fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonic acid [l-(4-fiuoro-benzyl)-3-oxo-2,3-<br>
dihydro-1 H-indazol-5-yl]-amide,<br>
2,4-Dichloro-N-[ l -(4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-6-methylbenzenesulfonamide,<br>
5-Chloro-2,4-difluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonam ide,<br>
4-Chloro-2,5-difluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonam ide,<br>
3-Chloro~[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
3-Cyano-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
Naphthalene-1-sulfonic acid [l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-<br>
yl]-amide,<br>
3-Chloro-4-fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluorobenzenesulfonamide,<br>
[l-(3,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluoro-3-trifluoromethylbenzenesulfonam<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide,<br>
[l-(3,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-3-trifluoromethoxybenzenesulfonamide,<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-5-methylbenzenesulfonamide,<br>
3,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide,<br>
4,5-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-fluorobenzenesulfonamide,<br>
2,4,5-Trichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonam ide,<br>
2,3-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide,<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-6-methylbenzenesulfonamide,<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluorobenzenesulfonamide,<br>
N-[l-(2,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-2,3-dihydro-l H-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
2,3-Dichloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
Naphthalene-1-sulfonic acid [l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-<br>
yl]-amide,<br>
3-Chloro-N-[l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-<br>
methyl-benzenesulfonamide,<br>
Naphthalene-1-sulfonic acid [l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl]-amide,<br>
2,3-Dichloro-N-[ l -(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-<br>
benzenesulfonamide,<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
N-[lK2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
difluoromethoxy-benzenesulfonamide,<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethoxy-benzenesulfonamide,<br>
3-Chloro-N-[ l -(2-cyano-ethyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
N-[l-(2-Cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifluoromethylbenzenesulfonam<br>
ide,<br>
2,4-Dichloro-N-[l-(2-cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-6-methylbenzenesulfonamide,<br>
3-Chloro-N-[l-(2-cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluorobenzenesulfonamide,<br>
N-[6-Chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
5-Chloro-N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-<br>
fluoro-benzenesulfonamide,<br>
2,3-Dichloro-N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonam ide,<br>
3-Chloro-N-(6-chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-2-<br>
methyl-benzenesulfonamide,<br>
N-(6-Chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-<br>
tri fluoromethyl-benzenesulfonamide,<br>
2-[5-(3-Chloro-2-methyl-benzenesulfonylamino)-3-oxo-2,3-dihydro-indazol-l-yl]-<br>
methyl-acetamide,<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2,3-dihydro-indazol-5-yl]-6-<br>
methyl-benzenesulfonamide, and<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2,3-dihydro-indazol-5-yl]-2-<br>
methyl-benzenesulfonamide,<br>
and pharmaceutically acceptable salts thereof.<br>
Examples of particularly preferred compounds of formula (I) are those selected<br>
front the group consisting of:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide,<br>
N-(lrBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,5-difluorobenzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluorobenzenesulfonamide,<br>
N-(UBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chloro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluorobenzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichlorobenzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-5-chloro-2-fluorobenzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide,<br>
3 -Cyano-[ l -(4-fluoro-benzyl)-3 -oxo-2,3 -dihydro-indazol-5 -yl] -benzenesulfonam ide,<br>
2,3-Dichloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
3-Chloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
4-Fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-4-fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide,<br>
N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide, and<br>
3-Chloro-2-methyl-N-(3-oxo-1 -pyridin-2-ylmethyl-2,3-dihydro-1 H-indazol-5-yl)-<br>
benzenesulfonamide,<br>
and pharmaceutically acceptable salts thereof.<br>
Other examples of preferred compounds of formula (I) are those selected from<br>
the group consisting of:<br>
2,3-Dichloro-N-(6-chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
N-(l'Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-difluorobenzenesulfonamide,<br>
2,4-Difluoro-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-2-fluoro-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-cyanobenzenesulfonamide,<br>
Propiane-2-sulfonic acid (l -benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-<br>
amide,<br>
3-Cyano-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
2,2,2-Trifluoro-ethanesulfonic acid (l-benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-<br>
5-yl)-amide,<br>
Propane-2-sulfonic acid (l -benzyl-6-chloro-3-oxo-2,3-dihydro- lH-indazol-5-yl)-<br>
amide,<br>
Propane-2-sulfonic acid [6-chloro-l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-<br>
5-yl]-amide,<br>
N-(lBenzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-trifluoromethanesulfonamide,<br>
Propane-2-sulfonic acid (l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
Propane-2-sulfonic acid [l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
amide,<br>
Propane-2-sulfonic acid [l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
amide, and<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-C-cyclopropyl-methanesulfonamide<br>
and pharmaceutically acceptable salts thereof.<br>
Another example of a particularly preferred compound of formula (I) is:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-C-cyclopropyl-methanesulfonamide<br>
and pharmaceutically acceptable salts thereof.<br>
It will be appreciated that the compounds of the present invention may be<br>
derivatised at funcţional groups to provide derivatives which are capable of<br>
conversion back to the parent compound in vivo. Physiologically acceptable and<br>
metabolically labile compounds, which are capable of producing the parent<br>
compounds of general formula (I) in vivo are also within the scope of the present<br>
invention.<br>
A further aspect of the present invention is the process for the preparation of<br>
compounds as defined above comprising the reaction of a compound of formula (II)<br>
(Figure Remove)wherein R1 to R7 are as defined above.<br>
Such a process can be carried out under conditions known to the person skilled<br>
in the art, e.g. in the presence of a base such as trietylamine or (4-dimetylamino)-<br>
pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or<br>
DMSO, or in pyridine as a solvent, with or without the addition of a base such as<br>
trietylamine or DMAP, at room temperature or at elevated temperatures.<br>
The invention further relates to compounds of formula (I) as described above,<br>
when prepared by a process as defined above.<br>
General description of the processes:<br>
The preparation of compounds of formula I of the present invention may be<br>
carried out in sequential or convergent synthetic routes. Syntheses of the invention are<br>
shown in the following schemes. The skills required for carrying out the reaction and<br>
purification of the resulting products are known to those persons skilled in the art. The<br>
subsţituents and indices used in the following description of the processes have the<br>
significance given above unless indicated to the contrary.<br>
In general, compounds of type I are readily accessible by sulfonylation of<br>
apprppriately substituted 5-amino-l,2-dihydro-indazol-3-one of formula Ila (R6=H)<br>
with sulfonyl chlorides, under various conditions that are known to persons skilled in<br>
 art. Examples of such conditions are - as indicated in Scheme l below - e.g.<br>
pyridine at elevated temperatures or THF under reflux conditions in the presence of a<br>
base such as potassium carbonate, sodium carbonate, sodium hydride, triethyl amine<br>
or the like. The sulfonyl chlorides are either commercially available or known in the<br>
literature or available in analogy to known procedures to those persons skilled in the<br>
(Figure Remove)Optionally, compounds of formula Ia with R6 = H obtained in this way can be further<br>
substituted at the sulfonamide nitrogen by treatment with a base such as sodium<br>
hydride, cesium carbonate, potassium carbonate or the like in a solvent such as DMF<br>
or THF or similar followed by alkylation of the resulting anion with an alkyl halide<br>
such as methyl iodide, ethyl bromide, benzyl bromide or the like in order to introduce<br>
the desired R6 substituent. Optionally, R6 can be introduced via alkylation of<br>
compound of formula Ila by procedures known to those persons skilled in the art.<br>
Appropriately substituted 5-amino-l,2-dihydro-indazol-3-ones of formula Ila are<br>
either known in the literature or can be made in analogy to literature procedures from<br>
known starting materials according to scheme 2- e.g. by condensation of the<br>
appropriately functionalized 2-fluorobenzoic acid of formula III with hydrazine<br>
hydrâte in ethanol and cyclisation under acidic conditions, followed by alkylation with<br>
R2-X to afford compounds of formula IVa (R6 = H), an opţional alkylation with R l-X<br>
(under thermal or basic conditions in analogy to procedures described in Heterocycles<br>
1997, 45, 129-36 or J. Med. Chem. 1991, 34, 1492-1503) to afford compounds of<br>
formula IV, and hydrogenation of the nitro group. (Schindler et al., Arch. Pharm.<br>
Pharm. Med. Chem., 1998, 357,13-21).<br>
Alternatively, appropriately substituted 5-amino-l,2-dihydro-indazol-3-ones of<br>
formula II are prepared according to the general Scheme 3 via a one-operation<br>
condensation of the appropriately functionalized 2-fluorobenzoic acid of formula III<br>
with an appropriately substituted hydrazine R1NHNH2 of formula V in the presence<br>
of a coupling agent in DMF, followed by an opţional alkylation with Rl-X (under<br>
therrnal or basic conditions in analogy to procedures described in Heterocydes 1997,<br>
45, 129-36 or J. Med Chem. 1991, 34, 1492-1503) and a reduction of the nitro group.<br>
5-Amino-l,2-dihydro-indazol-3-ones of formula II with R2 = aryl, heteroaryl can also<br>
be prepared in analogy to Menon et al., Combin. Chem. and High-Throughput<br>
Screen.2QQ3, 6, 471-480. The appropriately substituted starting materials of formula<br>
III are either commercially available or are known in the literature or were prepared in<br>
analogy to literature procedures from known starting materials. The corresponding<br>
substituted hydrazines of formula V are either commercially available or are known in<br>
the literature or synthesised in analogy to literature procedures (such as J. Org. Chem.<br>
1984, 49, 336-42; J. Am. Chem. Soc. 1986, 108, 7981-4 or Bioorg. Med. Chem. 2004,<br>
(Figure Remove)As described above, the compounds of formula (I) of the present invention can<br>
be used as medicaments for the treatment and/or prevention of diseases which are<br>
caused by disorders associated with the enzyme l Ibeta-hydroxysteroid dehydrogenase<br>
l (llbHSDl). Examples of such diseases are metabolic disorders, obesity,<br>
dyslipidemiae, hypertension and/or diabetes, particularly diabetes type II. The<br>
compounds of this invention can further be used in the prophylaxis and/or treatment<br>
of high ocular eye pressure, cognition, Alzheimer and/or neurodegeneration.<br>
The invention therefore also relates to pharmaceutical compositions comprising<br>
a compound as defined above and a pharmaceutically acceptable carrier and/or<br>
adjuvant.<br>
: Further, the invention relates to compounds as defined above for use as<br>
therapeutic active substances, particularly as therapeutic active substances for the<br>
treatment and/or prevention of diseases which are caused by disorders associated with<br>
the enzyme l Ibeta-hydroxysteroid dehydrogenase l (llbHSDl), particlularly as<br>
therapeutic active substances for the treatment and/or prevention of metabolic<br>
disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes<br>
type II.<br>
The invention further relates to a method for the treatment and/or prophylaxis of<br>
diseases which are caused by disorders associated with the enzyme l Ibetahydroxysteroid<br>
dehydrogenase l, particularly for the treatment and/or prophylaxis of<br>
metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly<br>
diabetes type II, which method comprises administering an effective amount of a<br>
compound as defined above.<br>
In another embodiment, the present invention relates to the use of compounds as<br>
defined above for the therapeutic and/or prophylactic treatment of diseases which are<br>
caused by disorders associated with the enzyme l Ibeta-hydroxysteroid dehydrogenase<br>
l, particularly for therapeutic and/or prophylactic treatment of metabolic disorders,<br>
obesity, dyslipidemiae, hypertension and/or diabetes, particularly type II diabetes.<br>
The invention further relates to the use of compounds as defmed above for the<br>
preparation of medicaments for the treatment and prophylaxis of diseases which are<br>
caused by disorders associated with the enzyme l Ibeta-hydroxysteroid dehydrogenase<br>
l, particularly for the treatment and prophylaxis of metabolic disorders, obesity,<br>
dyslipidemiae, hypertension and/or diabetes, particularly type II diabetes.<br>
Prevention and/or treatment of type II diabetes is the preferred indication.<br>
Assav Procedures<br>
Tranşient expression and parţial Purification:<br>
The cDNA encoding the human llbeta-HSDl protein was cloned into the expression<br>
vector pcDNAS (Stratagene). This construct (for details see Alex Odermatt et al.; J<br>
Biol Chem., 1999, Voi. 274, Issue 40, 28762-28770) was used to transiently express<br>
the protein in HEK293 cells (ATCC number: CRL-1573, described in Graham, F.L.,<br>
Smiley, J., Russell, W.C., Nairn, R.; (1977)) using lipofectamine. 48h after<br>
transfection cells were washed twice with ice-cold PBS (Phsophate buffered Saline).<br>
To l volume of cell suspension in PBS 2 volumes of ice-cold lysis buffer (50mM<br>
Tris; pH7.5; ImM EDTA; lOOmM NaCl) were added. The cells were lysed by Potterhomogenization<br>
(20 strokes). The resulting homogenate was sonicated wit a tip<br>
sonicator (10% output; 2 x 30 sec.) and cleared by a low speed centrifugation (lOmin<br>
x 9000g; 4°C). The microsomal fraction was collected by a high speed centrifugation<br>
(60 min x 110'OOOg). The resulting pellet was resuspended in storage buffer (20mM<br>
Tris pH 7.5; l mM EDTA; 10% Glycerol) and the centrifugation was repeated. The<br>
resulting pellet containing the microsomal fraction was again taken up into storage<br>
buffer and aliquots were kept frozen in liquid Nitrogen until use.<br>
Generation of stable cell linesexpressing llbeta-HSDl:<br>
The same construct used for transient expression of human llbeta-HSDl was also<br>
used to establish cell lines stably expressing the protein. Briefly, (HEK293) cells were<br>
transfected with l Ibeta-HSDl construct using the lipofectamine reagent (Gibco BRL)<br>
according to the manufacturer's instruction. Two days after transfection, geneticin<br>
selection (0.8 mg/ml) was initiated and several stable clones were isolated. Qne clone<br>
was further used for pharmacological characterization.<br>
Microsome Assay<br>
Microsomes isolated from HEK293 cells transiently expressing human llbeta-HSDl<br>
(for details see above) were incubated in assay buffer (100 mM NaCl; ImM EDTA;<br>
ImM EGTA; ImM MgCl; 250 mM Sucrose; 20 mM Tris pH 7.4; Cortisone 50-<br>
200nM and NADPH ImM) together with different concentrations of test substances.<br>
After 60 min. of incubation at 37°C the assay was stopped by heating to 80°C (5 min.)<br>
and by addition of the inhibitor Carbenoxolone (l uM). The amount of Cortisol<br>
produced in this assay was determined using a commercially available, ELISA-based<br>
Cortisol-detection kit (Distributed by Assay Design, Inc.). Inhibitors were<br>
characterized by there IC50 values, e.g. the concentration at which the production of<br>
cortisol was 50% reduced.<br>
Cellular Assay<br>
To measure the effect of inhibitors in intact cells HEK293 cells stably expressing<br>
human llbeta-HSDl (see above) were cultivated in 96 well plates in DMEM. First<br>
inhibitors and 60 min later Cortisone was added to the cells. After 60 min of<br>
incubation at 37°C in a 5% CO2 atmosphere part of the medium was removed and the<br>
conversion from Cortisone to Cortisol was measured using a commercially available<br>
ELISA kit (Distributed by Assay Design, Inc.).<br>
Results obtained in the microsome assay using representative compounds of the<br>
invention as the test compounds are shown in the following table:<br>
(Figure Remove)Compounds as described above have ICso values below 1000 nM; preferred<br>
compounds have ICso values below 100 nM. More preferred compounds have<br>
values below 10 nM. These results have been obtained by using the foregoing test.<br>
The compounds of formula I and their pharmaceutically acceptable salts and<br>
esters can be used as medicaments (e.g. in the form of pharmaceutical preparations).<br>
The pharmaceutical preparations can be administered internally, such as orally (e.g. in<br>
the form of tablets, coated tablets, drage"es, hard and soft gelatin capsules, solutions,<br>
emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in<br>
the form of suppositories). However, the administration can also be effected<br>
parentally, such as intramuscularly or intravenously (e.g. in the form of injection<br>
solutions).<br>
The compounds of formula I and their pharmaceutically acceptable salts and<br>
esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for<br>
the production of tablets, coated tablets, drage"es and hard gelatin capsules. Lactose,<br>
corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for<br>
example, as such adjuvants for tablets, drage"es and hard gelatin capsules.<br>
Suitable adjuvants for soft gelatin capsules, are, for example, vegetable oils,<br>
waxes, fats, semi-solid substances and liquid polyols, etc.<br>
Suitable adjuvants for the production of solutions and syrups are, for example,<br>
water, polyols, saccharose, invert sugar, glucose, etc.<br>
Suitable adjuvants for injection solutions are, for example, water, alcohols,<br>
polyols, glycerol, vegetable oils, etc.<br>
Suitable adjuvants for suppositories are, for example, natural or hardened oils,<br>
waxes, fats, semi-solid or liquid polyols, etc.<br>
Moreover, the pharmaceutical preparations can contain preservatives,<br>
solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers,<br>
sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers,<br>
masking agents or antioxidants. They can also contain still other therapeutically<br>
valuable substances.<br>
In accordance with the invention the compounds of formula I and their<br>
pharmaceutically acceptable salts can be used for the prophylaxis and treatment of<br>
28<br>
arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating<br>
disorders and obesity. The dosage can vary in wide limits and will, of course, be fitted<br>
to the individual requirements in each particular case. In general, in the case of oral<br>
administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably<br>
about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into<br>
preferably 1-3 individual doses, which can consist, for example, of the same amounts,<br>
shou}d be appropriate. It will, however, be clear that the upper limit given above can<br>
be exceeded when this is shown to be indicated.<br>
The invention is illustrated hereinafter by examples, which have no limiting<br>
character.<br>
Examples<br>
Example 1:<br>
N-(l-Benzyl-3-oxo-2-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide<br>
Step A] l-Benzyl-5-nitro-l,2-dihydro-indazol-3-one<br>
To a solution of 2-fluoro-5-nitrobenzoic acid (0.5 g) in DMF (9 mL) was added TBTU<br>
(1.04 g) followed by N-ethyldiisopropylamine (2.3 mL). After 10 minutes<br>
benzylhydrazine.2HCl (0.63 g) was added. The reaction mixture was stirred at<br>
ambient temperature for 22 hours and the reaction was poured onto aqueous IN HC1<br>
solution and extracted with EtOAc. The organic layer was washed with brine, dried<br>
over sodium sulfate, filtered and evaporated in vacuo. Purification via ISCO<br>
combiflash chromatography afforded pure desired l-benzyl-5-nitro-l,2-dihydroindazol-<br>
3-one (0.26 g) as a yellow solid. MS (ESr):268.3 ([M-H]").<br>
Step B] 5-Amino-l-benzyl-l,2-dihydro-indazol-3-one<br>
To a solution of l-benzyl-5-nitro-l,2-dihydro-indazol-3-one (0.44 g) in MeOH (50<br>
mL) was added Pd/C(10%) catalyst (0.1 g) and the reaction mixture was stirred for<br>
four hours at ambient temperature under a hydrogen atmosphere using a balloon. After<br>
this ţime the reaction mixture was filtered through Celite®which was washed with<br>
more EtOAc. The combined organic solution was evaporated in vacuo for afford the<br>
desired 5-amino-l-benzyl-l,2-dihydro-indazol-3-one (0.39 g) which was taken into<br>
the next reaction without further purification. MS (ESf): 240.1 ([M+H]+).<br>
Step C] N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonam<br>
ide<br>
To a solution of 5-amino-l-benzyl-l,2-dihydro-indazol-3-one (0.04 g) in pyridine (l<br>
mL) was added 3-chloro-2-methylbenzenesulfonylchoride (0.038 g) in one go. The<br>
solution was stirred at 60°C for 24 hours. The pyridine was then removed in vacuo<br>
and the residue was dissolved in EtOAc/water and separated. The aqueous phase was<br>
extracted a further two times with EtOAc and the combined organic phases were<br>
washed with brine and dried over sodium sulfate. The drying agent was removed by<br>
flltration and the volatiles were removed in vacuo to afford a crude residue. The crude<br>
material was purified via flash column chromatography eluting with<br>
EtOAc/nHeptane/l%AcOH) to afford the desired N-(l-benzyl-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl)-3-chloro-2-methyl-benzenesulfonamide (0.015 g) as a pale yellow<br>
Example 2:<br>
N-(l-BenzyI-3-oxo-2<lihydro-lh-indazol-5-yl></lihydro-lh-indazol-5-yl>
This; material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-4-fluoro-benzenesulfonyl chloride as an orange<br>
solid. MS (ESF): 430.3 ([M-H]').<br>
Example 3:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
This• material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-(trifluoromethyl)benzenesulfonyl chloride as a light<br>
N-(l-Benzyl-3-oxo-2-dihydro-lH-indazol-5-yl)-2,4-dichlorobenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2,4-dichlorobenzenesulfonyl chloride as a light yellow<br>
solid MS (ESP): 446.1 ([M-H]').<br>
Example 5:<br>
Naphthalene-2-sulfonic acid (l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 1-naphthalenebenzenesulfonyl chloride as a light yellow<br>
solid.<br>
MS (ESF): 428.4 ([M-H]').<br>
Example 6:<br>
N-(l-Benzyl-3-oxo-2-dihydro-lH-indazol-5-yl)-3-chloro-4-methylbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-4-methylbenzenesulfonyl chloride as a light<br>
yellow solid. MS (ESf): 428.4 ([M+Hf).<br>
Example 7:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-methoxy-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 4-methoxybenzenesulfonyl chloride as a light yellow solid.<br>
Example 8:<br>
N-(l"Benzyl-3-oxo-2-dihydro-lH-indazol-5-yl)-2,4-dichloro-6-methylbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2,4-dichloro-6-methylbenzenesulfonyl chloride as a brown<br>
solid MS (ESF): 460.1 ([M-H]').<br>
Example 9:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-trifluoromethylbenzenesulfonamide<br>
This; material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2-trifluoromethylbenzenesulfonyl chloride as a white solid.<br>
Example 10:<br>
N-(l-BenzyI-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-difluorobenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2,4-difluorobenzenesulfonyl chloride as a brown solid. MS<br>
Example 11:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-propyl-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 4-propylbenzenesulfonyl chloride as a light yellow solid.<br>
Example 12:<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonic acid (l-benzyl-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl)-amide<br>
This i material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2,3-dihydro-l,4-benzodioxine-6-sulfonyl chloride as an<br>
off-white solid. MS (ESf): 438.1 ([M+H]).<br>
Example 13:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-2,5-dimethylbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one (0.040 g) and 4-chloro-2,5-dimethylsulfonylchloride as an offwhite<br>
Example 14:<br>
N-(l-Benzyl-3-oxo-2-dihydro-H-indazol-5-yl)-4-chloro-3-trifluoromethyIbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-trifluoromethyl-4-chlorobenzenesulfonylchloride as a<br>
white solid. MS (ESI4): 482.3 ([M+H]+).<br>
Example 15:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazoI-5-yl)-4-fluoro-3-trifluoromethyIbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 4-fluoro-3-trifluoromethylbenzenesulfonylchloride as a<br>
light brown solid. MS (ESF): 464.4 ([M-H]').<br>
Example 16:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chloro-5-trifluoromethylbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 2-cloro-5-trifluoromethyl-benzenesulfonyl chloride as a<br>
lightbrown solid. MS (ESI"): 480.3[M-H]').<br>
Example 17:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazoI-5-yl)-3-phenoxy-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-penoxy-benzenesulfonyl chloride as a light brown solid.<br>
MS (ESF): 470.3[M-H]').<br>
Example 18:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-(5-methyl-[l,3,4]oxadiazol-2-<br>
yl)-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-(5-methyl-l,3,4-oxadiazol-2-yl)benzenesulfonyl chloride<br>
as a light brown solid. MS (ESF): 460.4[M-H]').<br>
Example 19:<br>
N-(l-Benzyl-3-oxo-2-dihydro-lH-indazol-5-yl)-3-chloro-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-benzenesulfonyl chloride as a light brown solid.<br>
MS(ESr):412.1[M-H]').<br>
Example 20:<br>
N-(l-BenzyI-3-oxo-2-dihydro-lH-indazol-5-yl)-3-methoxy-benzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-methoxy-benzenesulfonyl chloride as a light brown<br>
solid. MS (ESF): 408.0[M-H]-).<br>
Example 21:<br>
N-(l-Benzyl-3-oxo-23-dihydro-lH-indazol-5-yl)-3-difluoromethoxybenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3-(difluoromethoxy)-benzenesulfonyl chloride as a<br>
colorless solid. MS (ESI'): 444.1[M-H]').<br>
Example 22:<br>
N-(lrBenzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3,5-bis-trifluoromethylbenzenesulfonamide<br>
This l compound was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3,5-bistrifluoromethylbenzenesulfonyl chloride (step C) as<br>
a white solid. MS (EST): 514.3 [M-H]').<br>
Example 23:<br>
Propane-2-sulfonic acid (l-benzyI-3-oxo-2,3-dihydro-lH-indazol-5-yl)-ainide<br>
This compound was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and 3 propane-2-sulfonyl chloride (step C) as a white solid. MS<br>
Example 24:<br>
N-(lrBenzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-N-diraethylbenzenesulfonamide<br>
To a solution of NaH (0.005 g of a 60% dispersion in mineral oii) in DMF (2 mL) at<br>
0°C was added N-(l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide<br>
in DMF (l mL) dropwise. After 15 minutes Mei (0.017 g) was<br>
added and the reaction mixture was allowed to warm to ambient temperature. The<br>
reaction was quenched with water and diluted with EtOAc. The phases were separated<br>
and the aqueous phase was extracted with more EtOAc. The combined organic phases<br>
were washed with brine, dried over sodium sulfate, filtered and reduced in vacuo.<br>
Flash column chromatography over silica (EtOAc/nheptane) afforded the desired N-<br>
(l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-N-dimethylbenzenesulfonamide<br>
as an off-white solid (13 mg). MS (ESI): 442.4[M+H]+).<br>
Example 25:<br>
N-(3-Oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
Step A] l-Allyl-5-nitro-1,2-dihydro-indazol-3-one<br>
5-Niţro-l,2-dihydro-indazol-3-one (prepared according to Org. Synth. 1949, 29, 54 or<br>
Chem Ber. 1942, 75, 1104) (9.36 g) was suspended in 40 ml water and 57.5 ml IN<br>
KOH. Allyl bromide (6.32 g) was added in one portion. The mixture was stirred at<br>
75-80°C for 1.5 hours. Then NaOH (15%, 5 mL) and allyl bromide (l g) was added.<br>
The reaction mixture was stirred for a further 30 min. The mixture was neutralized<br>
with 3N HC1 at 
solid was then suspended in 10 ml ethyl acetate and stirred at ambient temperature for<br>
3 hojurs, then filtered and dried to afford the desired l-allyl-5-nitro-l,2-dihydroindazol-<br>
3-one (7.63 g) as a yellow solid.<br>
Step B] 35<br>
l-Allyl-5-nitroindazolone (1.42 g) and Pd/C (10%, 250 mg) were suspended in MeOH<br>
(50 mL) and hydrogenated (hydrogen balloon) at RT for 4-5 h (or overnight.) After<br>
filtration and removal of MeOH, the solid was dried in vacuo to afford the desired 5-<br>
amino-l-propyl-l,2-dihydro-indazol-3-one (1.2 g) as a crude oii. This material was<br>
used in the next reaction without any further purification.<br>
Step C] N-(3-Oxo-1 -propyl-2,3-dihydro-1H-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
This material was obtained in analogy to example l using 5-amino-l-propyl-l,2-<br>
dihydro-indazol-3-one and 2,3-dichlorobenzenesulfonyl chloride.<br>
Example 26:<br>
2,3-Dichloro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide<br>
This;material was obtained in analogy to example 25 using 5-amino-l-propyl-l,2-<br>
dihydro-indazol-3-one and 2,3-dichlorobenzenesulfonyl chloride.<br>
Example 27:<br>
3-Chloro-4-fluoro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yI)-<br>
benzenesulfonamide<br>
This material was obtained in analogy to example 25 using 5-amino-l-propyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-4-fluoro-benzenesulfonyl chloride.<br>
Example 28:<br>
3-CWoro-2-methyl-W-(3-oxo-l-phenethyl-2-dihydro-l/y-indazol-5-yl)-<br>
benzenesulfonamide<br>
This icompound was obtained in analogy to example l using phenethylhydrazine (step<br>
A) and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as a light yellow solid.<br>
MS (ESf): 442.3[M+Hf).<br>
Example 29:<br>
3-Chloro-4-methyl-W-(3-oxo-l-phenethyl-2,3-dihydro-l//-indazol-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example l using phenethylhydrazine (step<br>
A) and 3-chloro-4-methylbenzenesulfonyl chloride (step C) as a white solid. MS<br>
(ESlt): 442.3[M+H]+).<br>
Example 30:<br>
4-Chloro-2,5-dimethyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example l using phenethylhydrazine (step<br>
A) and 4-chloro-2,5-dimethylbenzenesulfonyl chloride (step C) aş a white solid. MS<br>
(ESlt): 456.4[M+H]+).<br>
Example 31:<br>
N-(3-Oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
This compound was obtained in analogy to example l using phenethylhydrazine (step<br>
A) and 3-trifluoromethylsulfonyl chloride (step C) as a red solid. MS (ESI4):<br>
462.1[M+H]+).<br>
Example 32:<br>
N-(l-IsobutyW-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
StepiA] l-Isobutyl-5-nitro-l,2-dihydro-indazol-3-one<br>
To a solution of 2-fluoro-5-nitrobenzoic acid (1.5 g) in DMF (50 mL) was added<br>
EDCI.HC1 (1.71 g) followed by N-ethyldiisopropylamine (5.51 mL). After 10 minutes<br>
isobutylhydrazine.p-toluenesulfonicacid salt (2.32 g) was added. The reaction mixture<br>
was stirred at ambient temperature for 22 hours and the reaction was poured onto<br>
aqueous IN HC1 solution and extracted with EtOAc. The organic layer was washed<br>
withibrine, dried over sodium sulfate, filtered and evaporated .in vacuo. Purification<br>
via ISCO combiflash chromatography afforded pure desired l-isobutyl-5-nitro-l,2-<br>
dihydro-indazol-3-one (0.9 g) as ayellow solid. MS (ESr):234.1 ([M-H]').<br>
Step B] 5-Amino-l-isobutyl-l,2-dihydro-indazol-3-one<br>
To a solution of l-isobutyl-5-nitro-l,2-dihydro-indazol-3-one (0.9 g) in MeOH (50<br>
mL) was added Pd/C(10%) catalyst (0.3 g) and the reaction mixture was stirred for l<br>
hour at 40°C under a hydrogen atmosphere using a balloon. After this time the<br>
reaction mixture was filtered through Celite®which was washed with more EtOAc.<br>
The combined organic solution was evaporated in vacuo for afford the desired 5-<br>
amino-l-isobutyl-l,2-dihydro-indazol-3-one (0.6 g) which was taken into the next<br>
reaction without further purification. MS (ESI): 206.1 ([M+H]+).<br>
Step C] N-(l-Isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
To a solution of 5-amino-l-isobutyl-l,2-dihydro-indazol-3-one (0.04 g) in pyridine (l<br>
mL) was added 3-trifluoromethylbenzenesulfbnylchoride (0.041 g) in one go. The<br>
solution was stirred at 60°C for 24 hours. The pyridine was then removed in vacuo<br>
and the residue was dissolved in EtOAc/water and separated. The aqueous phase was<br>
extracted a further two times with EtOAc and the combined organic phases were<br>
washed with brine and dried over sodium sulfate. The drying agent was removed by<br>
flltration and the volatiles were removed in vacuo to afford a crude residue. The crude<br>
material was purified via flash column chromatography eluting with<br>
EtOAc/nHeptane/l%AcOH) to afford the desired N-(l-isobutyl-3-oxo-2,3-dihydrolH-<br>
indazol-5-yl)-3-trifluoromethyl-benzenesulfonamide (0.015 g) as a pale yellow<br>
powder. MS (ESf): 414.4[M+H]+).<br>
Example33:<br>
3-Chloro-N-(l-isobutyl-3-oxo-2-dihydro-lH-indazol-5-yl)-4-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-4-methylbenzenesulfonyl chloride (step C) as a<br>
white solid. MS (ESI4): 394.1 [M+H]).<br>
Example 34:<br>
3-ChIoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yI)-2-methylbenzenesulfonamide<br>
38<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as a<br>
white solid. MS (ESI): 394. l [M+H]).<br>
Example 35:<br>
3-Cyano-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3-cyano-benzenesulfonyl chloride (step C) as an off-white<br>
solid MS (ESI): 371.1[M+H]+).<br>
Example 36:<br>
3-Difluoromethoxy-(l-isobutyl-3-oxo-2,3-dihydro--indazol-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3-difluoromethoxy-benzenesulfonyl chloride (step C) as an<br>
off-white solid. MS (ESf):<br>
Example 37:<br>
4-Cyano-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 4-cyano-benzenesulfonyl chloride (step C) as an off-white<br>
solid MS (ESf): 371.1 [M+H]+).<br>
Example 38:<br>
4-Fluoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethyIbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step<br>
C) as an off-white solid. MS (ESf): 432.4 [M+H]+).<br>
Example 39:<br>
39<br>
3-Chloro-4-fluoro-W-(l-isobutyl-3-oxo-2,3-dihydro-l//-indazol-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3-chloro-4-fluorobenzenesulfonyl chloride (step C) as an<br>
off-white solid. MS (ESI): 398.l [M+H]4).<br>
Example 40:<br>
2,4-Dichloro-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-5-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 2,4-dimethyl-5-methylbenzenesulfonyl chloride (step C) as<br>
an orange solid. MS (ESI+): 428.3 [M+H]+).<br>
Example 41:<br>
3-Chloro-N-(l-ethyl-3-oxo-2,3-dihydro-l#-indazol-5-yl)-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example l using ethylhydrazine.oxalate<br>
salt (step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as light yellow<br>
solid MS (ESf): 366.0 [M+H]).<br>
Example 42:<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using cyclopropylmethylhydrazine<br>
(step A) (prepared as described in J. Am. Chem. Soc. 1986, 108, 7981-4)<br>
and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as a light red solid. MS<br>
(ESI;): 392.0 [M+H]+).<br>
Example 43:<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using cyclopropylmethylhydrazine<br>
(step A) (prepared as described in J. Am. Chem. Soc. 1986, 108, 7981-4)<br>
: 40<br>
and 3-chloro-4-fluorobenzenesulfonyl chloride (step C) as a pink solid. MS (ESI+):<br>
396.3 [M+H]+).<br>
Example 44:<br>
(l-Cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using cyclopropylmethylhydrazine<br>
(step A) (prepared as described in J. Am. Chem. Soc. 1986, 108, 7981-4)<br>
and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as a light red solid.<br>
MS (ESf): 430.4 [M+H]).<br>
Example 45:<br>
3-Chloro-(l-cycIopropylmethyI-3-oxo-2,3-dihydro-indazoI-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using cyclopropylmethylhydrazine<br>
(step A) (prepared as described in V. Am. Chem. Soc. 1986, 108, 7981-4)<br>
and 3-chlorobenzenesulfonyl chloride (step C) as an orange solid. MS (ESI): 378.3<br>
Example 46:<br>
2,4-Dichloro-(l-cyclopropyImethyl-3-oxo-2y3-dihydro-indazol-5-yl)-5-methyIbenzenesulfonamide<br>
This i compound was obtained in analogy to example 32 using cyclopropylmethylhydrazine<br>
(step A) (prepared as described in J. Am. Chem. Soc. 1986, 1 08, 7981-4)<br>
and 2,4-dichloro-5-methylbenzenesulfonyl chloride (step C) as an orange solid. MS<br>
(ESlt):426.1 [M+H]+).<br>
Example 47:<br>
3-Chloro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using (2-methoxy-ethyl)-<br>
hydrâzine (step A) (prepared as described in J. Org. Chem. 1984, 49, 336-42) and 3-<br>
41<br>
chloro-2-methylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI): 396.3<br>
Example 48:<br>
4-Fluoro-[l-(2-methoxy-ethyl)-3-oxo-2-dihydro-indazol-5-yl]-3-trifluoroinethylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using (2-methoxy-ethyl)-<br>
hydrazine (step A) (prepared as described in J. Org. Chem. 1984, 49, 336-42) and 4-<br>
fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI):<br>
434.3 [M+H]+).<br>
Example 49:<br>
3-Chloro-4-fluoro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using (2-methoxy-ethyl)-<br>
hydrâzine (step A) (prepared as described in J. Org. Chem. 1984, 49, 336-42) and 3-<br>
chloro-4-fluorobenzenesulfonyl chloride (step C) as an off-white solid. MS (ESI+):<br>
400.3 [M+HJ+).<br>
Example 50:<br>
2,4-DichIoro-[l-(2-methoxy-ethyl)-3-oxo-2r3-dihydro-indazol-5-yl]-6-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using (2-methoxy-ethyl)-<br>
hydrâzine (step A) (prepared as described in J. Org. Chem. 1984, 49, 336-42) and 2,4-<br>
dichlbro-6-methylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI+):<br>
430.3 [M+Hf).<br>
Example 51:<br>
3-ChIoro-2-methyl-A'-[3-oxo-l-(2,2-trifluoro-ethyl)-2,3-dihydro-l/r-indazol-5-<br>
yl]-benzenesulfonamide<br>
Thisicompound was obtained in analogy to example 32 using (2,2,2-trifluoro-ethyl)-<br>
hydrazine (step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as a red<br>
solii MS (ESf): 420.3 [M+H]+).<br>
Example 52:<br>
4-Fliioro-[3-oxo-l-(2,2,2-trifluoro-ethyl)-2,3-dihydro-indazol-5-yl]-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using (2,2,2-trifluoro-ethyl)-<br>
hydrazine (step A) and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as<br>
a brown solid. MS (ESf): 458.4 [M+H]+).<br>
Example 53:<br>
4-FIuoro-A3-oxo-l-pyridin-2-ylmethyI-2,3-dihydro-l/y-indazol-5-yl)-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This; compound was obtained in analogy to example 32 using pyridin-2-ylmethylhydrazine<br>
(step A) (prepared in analogy to examples described in J. Org. Chem. 1984,<br>
49, 336-42) and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as offwhite<br>
solid. MS (ESf): 467.4 [M+H]+).<br>
Example 54:<br>
2,4-Dichloro-6-methyl-A43-oxo-l-pyridin-2-ylmethyl-2-dihydro-l//-indazol-5-<br>
yl)-benzenesulfonamide<br>
This; compound was obtained in analogy to example 32 using pyridin-2-ylmethylhydrazine<br>
(step A) (prepared in analogy to examples described in J. Org. Chem. 1984,<br>
49, 336-42) and 2,4-dichloro-6-methylbenzenesulfonyl chloride (step C) as off-white<br>
solid MS (ESf): 463.3 [M+H]).<br>
Example 55:<br>
3-Chloro-2-methyl-V-(3-oxo-l-pyridin-2-ylmethyl-2-dihydro-ljy-indazdI-5-yl)-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using pyridin-2-ylmethylhydrazine<br>
(step A) (prepared in analogy to examples described in J. Org. Chem. 1984,<br>
49, 336-42) and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as off-white<br>
solid MS (ESf): 429.4 [M+H]+).<br>
Example 56:<br>
4-Fluoro-A'-[l-(2-hydroxy-2-methyl-propyl)-3-oxo-2,3-dihydro-lr-indazoI-5-yl]-<br>
3-trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using pyridin-2-ylmethylhydrazine<br>
(step A) (prepared as described in Bioorg. Med. Chem. 2004, 12, 1357-<br>
1366) and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as off-white<br>
solid, MS (ESI): 448.3 [M+Hf).<br>
Example 57:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-4-<br>
fluorobenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI"): 464.1 [MExample<br>
58:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 4-fluoro-3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESF):<br>
498.0 [M-H]&gt;<br>
Example 59:<br>
N-(lrBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-2-<br>
methylbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI"): 460.0 [MExample<br>
N-(l-Benzyl-6-chIoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitrorbenzoic acid, benzylhydrazine.2HCl (step A) and 2,3-dichloro-benzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI'): 480.1 [M-H]').<br>
Example 61:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-cyanobenzenesulfonamide<br>
This i compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-cyano-benzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESF): 437.0 [M-H]').<br>
Example 62:<br>
N-(lBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-benzenesulfonyl<br>
chloride (step C) as a white solid. MS (ESF): 446.l [M-H]').<br>
Example 63:<br>
N-(l"Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 4-chloro-3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a white solid.<br>
MS(ESr):514.3[M-HD.<br>
Example 64:<br>
N-(l--Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-difluoromethoxybenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 4-chloro-3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a white solid.<br>
MS (ESF): 478.0 [M-H]').<br>
Example65:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-trifluoromethyIbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 2-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI"): 480.0<br>
[M-H]-).<br>
Example 66:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethoxybenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitrol-benzoic acid, benzylhydrazine.2HCl (step A) and 3-<br>
triflupromethoxybenzenesulfonyl chloride (step C) as a white solid. MS (ESF): 496.4<br>
[M-H]').<br>
Example 67:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,5-difluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitror-benzoic acid, benzylhydrazine.2HCl (step A) and 2,5-difluorobenzenesulfonyl<br>
chloride (step C) as a light red solid. MS (ESF): 447.9 [M-H]').<br>
Example 68:<br>
N-(l-Benzyl-6-chIoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitroţ-benzoic acid, benzylhydrazine.2HCl (step A) and 2,4-dichlorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI+): 482.4 [M+Hf).<br>
Example 69:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluorobenzenesulfonamide<br>
This \ compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-2-<br>
fluorobenzenesulfonyl chloride (step C) as a yellow solid. MS (ESI"): 464.1 [M-H]").<br>
Example 70:<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a light red solid. MS (ESF): 480.0<br>
[M-H]-).<br>
Example 71:<br>
N-(lBenzyI-6-chloro-3-oxo-2,3-dihydro-lH-indazoI-5-yl)-5-chloro-2-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-6-<br>
fluorobenzenesulfonyl chloride (step C) as a brown solid. MS (ESI'): 464.1 [M-H]").<br>
Example 72:<br>
N-(lBenzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 2-chlorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI"): 446.1 [M-H]").<br>
Example 73:<br>
(l-Benzyl-4-chIoro-3-oxo-2,3-dihydro-indazol-5-yl)-3-chloro-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2-chloro-6-fluoro-3-<br>
nitrorbenzoic acid, benzylhydrazine.2HCl (step A) and 3-chloro-4-<br>
fluorpbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI"): 460.1 [MH]-).<br>
Example 74:<br>
N-(lBenzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazoI-5-yl)-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 4-fluoro-3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESF1):<br>
484.5 [M+H]+).<br>
Example 75:<br>
N-(l-Benzyl-6-fluoroO-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 2,3-dichlorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESF): 464.1 [M-H]').<br>
Example 76:<br>
N-(l-BenzyI-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichlorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 2,4-dichlorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI'): 464. l [M-H]").<br>
Example 77:<br>
(l-Benzyl-â-fluoro-S-oxo-dihydro-lH-indazol-S-yO-S-chloro-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzbic<br>
acid, benzylhydrazine.2HCl (step A) and 3-chloro-2-fluorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI'): 447.9 [M-H]").<br>
N-(lBenzyI-6-fluoro-3-oxo-2-dihydro-lH-indazoI-5-yl)-5-chloro-2-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 3-chloro-6-fluorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI'): 447.9[M-H]").<br>
Example 79:<br>
N-(l-Benzyl-6-fluoro-3-oxo-2-dihydro-lH-indazol-5-yl)-3-trifluoromethoxybenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 3-trifluoromethoxybenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI): 482.4 [M+H]+).<br>
Example 80:<br>
3-CHloro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazoI-5-yl]-<br>
benzenesulfonamide<br>
Step A] l-(4-Fluoro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one<br>
5-Nitro-l,2-dihydro-indazol-3-one (prepared according to Org. Synth. 1949, 29, 54 or<br>
Chem Ber. 1942, 75, 1104) (0.7 g) was suspended in l N NaOH (4.2 mL) and stirred<br>
for 10 minutes at 75°C. 4-Fluorobenzylbromide (0.48 mL) was then added dropwise<br>
over 2 hours. The reaction was stirred overnight and was quenched with 2 N HCI (aq.)<br>
solution while cooling in an ice bath. The precipitate was collected by fîltration and<br>
the crude solid was either purified by flash column chromatography or by trituration<br>
with ether to give pure l-(4-fluoro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one. MS<br>
(ESI1): 286.1 [M-H]').<br>
Step B] 5-Am ino-1 -(4-fluoro-benzyl)-1,2-dihydro-indazol-3 -one<br>
To a solution of l-(4-fluoro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one (0.81 g) in<br>
MeOH (100 mL) was added Pd/C(10%) catalyst (0.1 g) and the reaction mixture was<br>
stirred for three hours at 40°C under a hydrogen atmosphere using a balloon. After<br>
this time the reaction mixture was filtered through Celite®which was washed with<br>
more EtOAc. The combined organic solution was evaporated in vacuo for afford the<br>
desired 5-amino-l-(4-fluoro-benzyl)-l,2-dihydro-indazol-3-one (0.617 g) which was<br>
taken into the next reaction without further purification. MS (ESf): 258.3 ([M+H]+).<br>
Step C] 3-Chloro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide<br>
To a solution of 5-amino-l-(4-fluoro-benzyl)-l,2-dihydro-indazol-3-one (0.100 g) in<br>
pyridine (l mL) was added 3-chlorobenzenesulfonylchoride (0.082 g) in one go. The<br>
solution was stirred at 60°C for 24 hours. The pyridine was then removed in vacuo<br>
and the residue was dissolved in EtOAc/water and separated. The aqueous phase was<br>
extracted a further two times with EtOAc and the combined organic phases were<br>
washed with brine and dried over sodium sulfate. The drying agent was removed by<br>
filtration and the volatiles were removed in vacuo to afford a crude residue. The crude<br>
material was purified via flash column chromatography eluting with<br>
EtOAc/nHeptane/l%AcOH) to afford the desired 3-chloro-N-[l-(4-fluoro-benzyl)-3-<br>
oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide (0.087 g) as a brown solid.<br>
MS (ESI): 432.4 [M+H]).<br>
Example 81:<br>
3-Difluoromethoxy-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-ylJbenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-difluoromethoxybenzenesulfonyl chloride<br>
(step C) as a light brown solid. MS (ESI): 464.4 [M+Hf).<br>
Example 82:<br>
4-FlMoro-N-[l-(4-fluoro-benzyl)-3-oxo-2-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This i compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
1,2-dihydro-indazol-3-one and 4-fluoro-3-trifluoromethylbenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESF): 482.3 [M-H]').<br>
Example 83:<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonic acid [l-(4-fluoro-benzyl)-3-oxo-2,3-<br>
dihydro-lH-indazol-5-yl]-amide<br>
50<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-dihydro-l,4-benzodioxine-6-sulfonyl<br>
chloride (step C) as a light brown solid. MS (ESF): 456.5 [M-H]').<br>
Example 84:<br>
2,4-Dich!oro-N-[l-(4-fluoro-benzyl)-3-oxo-2v3-dihydro-lH-indazol-5-yI]-6-<br>
methyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 2,4-dichloro-6-methylbenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESf): 480.4 [M+H]+).<br>
Example 85:<br>
5-Chloro-2,4-difluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-chloro-4,6-difluorobenzenesulfonyl chloride<br>
(step; C) as an off-white solid. MS (ESI): 468.4 [M+H]+).<br>
Example 86:<br>
4-ChIoro-2,5-difluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 4-chloro-2,5-difluorobenzenesulfonyl chloride<br>
(step; C) as an off-white solid. MS (ESf): 468.4 [M+H]+).<br>
Example 87:<br>
3-CKloro—[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydrO-indazol-3-one and 3-chloro-2-methylbenzenesulfonyl chloride<br>
(step; C) as an ofiwhite solid. MS (ESf): 446.0 [M+H]+).<br>
Example 88:<br>
l 51<br>
3-Cyano-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-cyanobenzenesulfonyl chloride (step C) as<br>
light brown solid. MS (ESI): 423.1 [M+H]4).<br>
Example 89:<br>
Naphthalene-l-sulfonic acid [l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-<br>
5-yl]-amide<br>
This; compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydfo-indazol-3-one and 1-naphthalenesulfonyl chloride (step C) as<br>
lightibrown solid. MS (ESI): 448.3 [M+H]+).<br>
Example 90:<br>
3-Chloro-4-fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazoI-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 5-amino-l-(4-fluorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-chloro-4-fluorobenzenesulfonyl chloride<br>
(step; C) as light brown foam. MS (ESI): 449.9 [M+H]).<br>
Example 91:<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step<br>
C) as a white solid. MS (ESf): 464.3 [M+H].<br>
Example 92:<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3-chloro-4-fluorobenzenesulfonyl chloride (step<br>
C) as a white solid. MS (ESf): 468.4 [M+H]).<br>
Example 93:<br>
[l-(3,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluprobenzylbromide (step A) and 4-fluoro-3-trifluoromethylbenzenesulfonyl<br>
chloride (step C) as a white solid. MS (ESI4): 502.1 [M+H]+).<br>
Example 94:<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3-chlorobenzenesulfonyl chloride (step C) as an<br>
organge solid. MS (ESf): 450.3 [M+H]).<br>
Example 95:<br>
[l-(3,4-Difluoro-benzyI)-3-oxo-2,3-dihydro-indazoI-5-yI]-3-trifluoromethoxybenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluQrobenzylbromide (step A) and 3-trifluoromethoxybenzenesulfonyl chloride (step<br>
C) as a white solid. MS (ESI1): 500.3 [M+H]).<br>
Example 96:<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-5-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
diflubrobenzylbromide (step A) and 2,4-dichloro-5-methylbenzenesulfonyl chloride<br>
(step C) as a white solid. MS (ESI): 498.4 [M+H]+).<br>
Example 97:<br>
3,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazoI-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3,4-dichloro-benzenesulfonyl chloride (step C) as<br>
a white solid. MS (ESI4): 484.4 [M+H]+).<br>
Example 98:<br>
4,5-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazoI-5-yl]-2-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3,4-dichloro-6-fluorobenzenesulfonyl chloride<br>
(step C) as a white solid. MS (ESf): 502.1 [M+H]+).<br>
Example 99:<br>
2,4,5-Trichloro-[l-(3,4-difluoro-benzyl)-3-oxo-23-dihydro-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3,4,6-trichloro-benzenesulfonyl chloride (step C)<br>
as a white solid. MS (ESI): 520.3 [M+H]+).<br>
Example 100:<br>
2,3-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
diflubrobenzylbromide (step A) and 2,3-dichlorobenzenesulfonyl chloride (step C) as<br>
a white solid. MS (ESI): 484.4 [M+H]+).<br>
Example 101:<br>
2,4-DichIoro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-6-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 2,4-dichloro-6-methylbenzenesulfonyl chloride<br>
(step C) as a white solid. MS (ESf): 500.3 [M+H]+).<br>
Example 102:<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-23-dihydro-lH-indazol-5-yl]-4-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 2,4-<br>
difluorobenzylbromide (step A) and 3-chloro-4-fluorobenzenesulfonyl chloride (step<br>
C) as a pink solid. MS (ESf): 468.4 [M+H]"1").<br>
Example 103:<br>
N-[l-(2,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazoI-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 2,4-<br>
difludrobenzylbromide (step A) and 4-fluoro-3-trifluoromethylbenzenesulfonyl<br>
chloride (step C) as a white solid. MS (ESI): 502. l [M+H]+).<br>
Example 104:<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-2,3-dihydro-l H-indazol-5-yl]-2-<br>
methyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 80 using 2,4-<br>
difluorobenzylbromide (step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step<br>
C) as a white solid. MS (ESf): 464.3 [M+H]).<br>
Example 105:<br>
N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
Step A] l -(4-Chloro-benzyl)-5-nitro-1,2-dihydro-indazol-3-one<br>
This compound was obtained in analogy to step A in example 77 using 5-nitro-l,2-<br>
dihydro-indazol-3-one (prepared according to Org. Synth. 1949, 29, 54 or Chem Ber.<br>
1942, 75, 1 104) and 4-chlorobenzylbromide to afford the desired l -(4-chloro-benzyl)-<br>
5-nitro-l,2-dihydro-indazol-3-one as a brown solid. MS (ESI'): 302.3 [M-H]').<br>
Step B] 5-Amino-l-(4-chloro-benzyl)-l,2-dihydro-indazol-3-one<br>
To l-(4-chloro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one (0.45 g) was added HC1<br>
(37% aq.) solution (5 mL) followed by SnCl2.dihydrate (1.9 g). The mixture was<br>
heated to 85 °C for one hour. The reaction was then neutralized with sodium<br>
bicarbonate solution, filtered, and the filtrate extracted with EtOAc. The combined<br>
organic phases were washed with brine, dried over sodium sulfate, filtered and<br>
reduced in vacuo. Flash column chromatography of the residue over silica gel eluting<br>
with methylene chloride/methanol afforded the desired 5-amino-l-(4-chloro-benzyl)-<br>
l,2-dihydro-indazol-3-one (0.31 g) as a dark brown solid. MS (ESI): 274.4 [M+H]+).<br>
Step C] N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to step C in example 77 using 4-fluoro-3-<br>
trifluoromethylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI+): 500.3<br>
Example 106:<br>
3-Chloro-N-[l-(4-chloro-benzyl)-3-oxo-2-dihydro-lH-indazoI-5-yl]-2-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 5-amino-l-(4-chlorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 3-chloro-2-methylbenzenesulfonyl chloride<br>
(step C) as a light brown solid. MS (ESf): 462.1 [M+H]+).<br>
Example 107:<br>
2,3-Dichloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 5-amino-l-(4-chlorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 2,3-dichlorobenzenesulfonyl chloride (step C)<br>
as a light brown solid. MS (ESf): 482.4 [M+H]+).<br>
Example 108:<br>
Naphthalene-1-sulfonic acid [l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-<br>
5-yl]-amide<br>
This compound was obtained in analogy to example 105 using 5-amino-l-(4-chlorobenzyl)-<br>
l,2-dihydro-indazol-3-one and 1-naphthalenesulfonyl chloride (step C) as an<br>
off-white solid. MS (ESI): 464.1 [M+H]).<br>
Example 109:<br>
3-ChIoro-N-[l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazoI-5-yl]-2-<br>
methyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorbbenzylbromide (step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step C)<br>
as a light brown solid. MS (ESf): 480.4 [M+H]+).<br>
Example 110:<br>
Naphthalene-1-sulfonic acid [l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl]-amide<br>
This compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorbbenzylbromide (step A) and 1-naphthalenesulfonyl chloride (step C) as a light<br>
brown solid. MS (ESI): 482.4 [M+H]+).<br>
Example 111:<br>
2,3-Dichloro-N-[l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yI]-<br>
benzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorobenzylbromide (step A) and 2,3-dichlorobenzenesulfonyl chloride (step C) as a<br>
light brown solid. MS (ESI4): 500.1 [M+H]+).<br>
Example 112:<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yI]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorobenzylbromide (step A) and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride<br>
(step C) as an off-white solid. MS (ESF): 516.2 [M-H]').<br>
Example 113:<br>
N-[l-(2-Chloro-4-fluoro-benzyI)-3-oxo-2,3-dihydro-lH-indazol-5-yI]-3-<br>
difluoromethoxy-benzenesulfonamide<br>
This compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorobenzylbromide (step A) and 3-difluoromethoxybenzenesulfonyl chloride (step<br>
C) as a light brown solid. MS (ESF): 496.3 [M-HD.<br>
Example 114:<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-<br>
trifluoromethoxy-benzenesulfonamide<br>
This i compound was obtained in analogy to example 105 using 2-chloro-4-<br>
fluorobenzylbromide (step A) and 3-trifluoromethoxybenzenesulfonyl chloride (step<br>
C) as an off-white solid. MS (ESI): 514.3 [M-H]').<br>
Example 115:<br>
3-Chloro-N-[l-(2-cyano-ethyl)-3-oxo-2r3-dihydro-lH-indazol-5-yl]-2-methylbenzenesulfonamide<br>
Step A] 3-(5-Nitro-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile<br>
5-Nitro-l,2-dihydro-indazol-3-one (prepared according to Org. Synth. 1949, 29, 54 or<br>
Chem Ber. 1942, 75, 1104) (0.6 g) was suspended in water (8 mL) and 2N K2CO3<br>
(aq.) (1.8 g) was added to the flask and the mixture was heated to 50°C for 10<br>
minutes. Acrylonitrile (0.24 mL) was then added dropwise. The reaction was stirred<br>
overnight and was quenched with 2 N HC1 (aq.) solution while cooling in an ice bath.<br>
The aqueous phase was extracted with EtOAc and the combined phases were washed<br>
with brine, dried over sodium sulfate, filtered and reduced in vacuo. Fash column<br>
chromatography over silica gel (eluting with EtOAc, nheptane, 3% AcOH) afforded<br>
pure desirede 3-(5-Nitro-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile as a white<br>
solid, M<br>
Step B] 3-(5-Amino-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile<br>
To a solution of 3-(5-Nitro-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile (0.521 g) in<br>
MeOH (50 mL) was added Pd/C(10%) catalyst (0.13 g) and the reaction mixture was<br>
stirred for 20 hours at ambient temperature under a hydrogen atmosphere using a<br>
balloon. After this time the reaction mixture was filtered through Celite®which was<br>
washed with more EtOAc. The combined organic solution was evaporated in vacuo<br>
for afford the desired 3-(5-amino-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile (0.45<br>
g) which was taken into the next reaction without further purification. MS (ESI+):<br>
203.4 ([M+H]).<br>
Step C] 3-Chloro-N-[l-(2-cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-<br>
methyl-benzenesulfonamide<br>
To a solution of 3-(5-amino-3-oxo-2,3-dihydro-indazol-l-yl)-propionitrile (0.08 g) in<br>
pyridine (l mL) was added 3-chloro-2-methylbenzenesulfonylchoride (0.089 g) in one<br>
go. The solution was stirred at 60°C for 24 hours. The pyridine was then removed in<br>
vacuo and the residue was dissolved in EtOAc/water and separated. The aqueous<br>
phase was extracted a further two times with EtOAc and the combined organic phases<br>
were washed with brine and dried over sodium sulfate. The drying agent was removed<br>
by filtration and the volatiles were removed in vacuo to afford a crude residue. The<br>
crude material was purified via flash column chromatography eluting with<br>
EtOAc/nHeptane/l%AcOH) to afford the desired 3-Chloro-N-[l-(2-cyano-ethyl)-3-<br>
oxo-2,3-dihydro-lH-indazol-5-yl]-2-methyl-benzenesulfonamide (0.087 g) as a light<br>
brown solid. MS (ESf): 391.0 [M+H]+).<br>
Example 116:<br>
N-[l-(2-Cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethylbenzenesulfonamîde<br>
This compound was obtained in analogy to example 115 using 3-(5-amino-3-oxo-2,3-<br>
dihydro-indazol-1 -yl)-propionitrile and 4-fluoro-3-trifluoromethylbenzenesulfonyl<br>
chloride (step C) as a white solid. MS (ESI): 429.5 [M+H]+).<br>
Example 117:<br>
2,4-Dichloro-N-[l-(2-cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-6-methylbenzenesulfonamide<br>
This compound was obtained in analogy to example 115 using 3-(5-amino-3-oxo-2,3-<br>
dihydro-indazol-l-yl)-propionitrile and 2,4-dichloro-6-methylbenzenesulfonyl<br>
chloride (step C) as a light red solid. MS (ESI): 425.3 [M+Hf).<br>
Example 118:<br>
3-Chloro-N-[l-(2-cyano-ethyl)-3-oxo-2-dihydro-lH-indazoI-5-yl]-4-fluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 115 using 3-(5-amino-3-oxo-2,3-<br>
dihydro-indazol-l-yl)-propionitrile and 3-chloro-4-fluorobenzenesulfonyl chloride<br>
(step C) as a light red solid. MS (ESf): 395.3 [M+H]+).<br>
Example 119:<br>
N-[6-Chloro-l-(2-chloro-benzyl)-3-oxo-2v3-dihydro-lH-indazol-5-yl]-4-fluoro-3-<br>
trifluoromethyl-benzenesulfonamide<br>
Step A] 6-Chloro-l-(2-chloro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one<br>
6-Chloro-5-nitro-l,2-dihydro-indazol-3-one (prepared in analogy to Org. Synth. 1949,<br>
29, 54 or Chem Ber. 1942, 75, 1104 from 4-chloro-2-fluoro-5-nitro-benzoic acid over<br>
two steps) (0.6 g) was suspended in water (5 mL) and 2N KCOs (aq.) (l g) was added<br>
to the flask and the mixture was heated to 50°C for 10 minutes. 2-<br>
Chlorobenzylbromide (0.40 g) was then added dropwise. The reaction was stirred<br>
overnight and was neutralised with 2 N HC1 (aq.) while cooling in an ice bath. The<br>
precipitate was collected by filtration and triturated with diethylether to afford pure<br>
desired 6-chloro-l-(2-chloro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one as a brown<br>
solid MS (ESP: 336.3[M-H]").<br>
Stepfl] 5-Amino-6-chloro-l-(2-chloro-benzyl)-l,2-dihydro-indazol-3-one<br>
To ;6-chloro-l-(2-chloro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one (0.49 g) was<br>
added HC1 (37% aq.) solution (4 mL) followed by SnCl2.dihydrate (2.6 g). The<br>
mixture was heated to 85°C for one hour. The reaction was then neutralized with<br>
sodium bicarbonate solution, filtered, and the filtrate extracted with EtOAc. The<br>
combined organic phases were washed with brine, dried over sodium sulfate, filtered<br>
and reduced in vacuo. Flash column chromatography of the residue over silica gel<br>
eluting with methylene chloride/methanol afforded the desired 5-amino-6-chloro-l-(2-<br>
chloro-benzyl)-l,2-dihydro-indazol-3-one (0.33 g) as a yellow solid. MS (ESf): 308.3<br>
Step C] N-[6-Chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-<br>
fluorp-3-trifluoromethyl-benzenesulfonamide<br>
To a solution of 5-amino-6-chloro-l-(2-chloro-benzyl)-l,2-dihydro-indazol-3-one<br>
(0.070 g) in pyridine (l mL) was added f-fluoro-3-<br>
trifluoromethylbenzenesulfonylchoride (0.072 g) in one go. The solution was stirred at<br>
60°C for 24 hours. The pyridine was then removed in vacuo and the residue was<br>
dissplved in EtOAc/water and separ ated. The aqueous phase was extracted a further<br>
two times with EtOAc and the combined organic phases were washed with brine and<br>
dried over sodium sulfate. The drying agent was removed by filtration and the<br>
volatiles were removed in vacuo to afford a crude residue. The crude material was<br>
purified via flash column chromatography eluting with EtOAc/nHeptane/l%AcOH) to<br>
afford the desired N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-<br>
yl]-4i-fluoro-3-trifluoromethyl-benzenesulfonamide (0.024 g) as a light brown solid.<br>
MS (ESf): 534.3 [M+H]+).<br>
Example 120:<br>
5-Chloro-N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-<br>
fluoro-benzenesulfonamide<br>
This compound was obtained in analogy to example 119 using 5-amino-6-chloro-l-(2-<br>
chloro-benzyl)- 1 ,2-dihydro-indazol-3-one and 3-chloro-6-fluorobenzenesulfbnyl<br>
chloride (step C) as a light brown solid. MS (ESf): 500.3 [M+H]+).<br>
Example 121:<br>
2-Dichloro-N-[6-chloro-l-(2-chloro-benzyI)-3-oxo-2,3-dihydro-lH-indazoI-5-<br>
yl]-benzenesulfonamide<br>
This compound was obtained in analogy to example 119 using 5-amino-6-chloro-l-<br>
(2-chloro-benzyl)-l,2-dihydro-indazol-3-one and 2,3-dichlorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI): 5 1 8.0 [M+H]+).<br>
Example 122:<br>
3-Chloro-N-(6-chloro-3-oxo-l-pyridin-2-ylmethyl-2-dihydro-lH-indazol-5-yl)-<br>
2-methyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 119 using 2-chloromethylpyridine<br>
(step A) and 3-chloro-2-methylbenzenesulfonyl chloride (step C) as an offwhite<br>
solid. MS (ESO: 463.1 [M+H].<br>
Example 123:<br>
N-(6-Chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-<br>
3-trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 119 using 2-chloromethylpyridine<br>
(step A) and 4-fluoro-3-trifluoromethylbenzenesulfonyl chloride (step C) as a<br>
white solid. MS (ESf): 501.4[M+H]+).<br>
Example 124:<br>
2-[5-(3-Chloro-2-methyI-benzenesulfonylamino)-3-oxo-2,3-dihydro-indazol-l-yI]-<br>
methyl-acetamide<br>
Part A] (5-Nitro-3-oxo-2,3-dihydro-indazol-l-yl)-acetic acid ethyl ester<br>
This ;compound was obtained in analogy to example l (step A) using hydrazino-acetic<br>
acid ethyl ester.HCl as an orange solid. MS (ESF): 264.1[M-H]~).<br>
Part B] (5-Nitro-3-oxo-2,3-dihydro-indazol-l-yl)-acetic acid<br>
To a| solution of (5-nitro-3-oxo-2,3-dihydro-indazol-l-yl)-acetic acid ethyl ester (0.24<br>
g) in THF (9 mL), was added 2 N NaOH (aq.) (1.8 mL). The reaction mixture was<br>
stirred at ambient temperature for 30 minutes. The reaction mixture was acidified with<br>
2 N HC1 (aq.) and extracated with EtOAc. Evaporation of the organic phases afforded<br>
the desired crude (5-nitro-3-oxo-2,3-dihydro-indazol-l-yl)-acetic acid (0.146 g) which<br>
was taken into the next step without further purification.<br>
Part C] N-Methyl-2-(5-nitro-3-oxo-2,3-dihydro-indazol-1 -yl)-acetamide<br>
To a solution of crude (5-nitro-3-oxo-2,3-dihydro-indazol-l-yl)-acetic acid (0.14 g) in<br>
DMF, was added TBTU (0.20 g), followed by N,N-ethyldiisopropylamine (0.40 mL)<br>
and after 10 minutes methylamine (0.32 mL of a 2 M solution) was added. The<br>
reaction was stirred overnight and was quenched with 2N HC1 (aq.) and extracted with<br>
EtOAc. The combined organic layers were washed with brine, dried over sodium<br>
sulfate, filtered and evaporated. Flash column chromatography of the residue over<br>
silica gel afforded the desired N-methyl-2-(5-nitro-3-oxo-2,3-dihydro-indazol-l-yl)-<br>
acetamide (0.040 g) as a yellow solid. MS (ESF): 249.1 ([M-H]').<br>
Part D and E] 2-[5-(3-Chloro-2-methyl-benzenesulfonylamino)-3-oxo-2,3-<br>
dihydro-indazol-1-yl]-methyl-acetamide<br>
This compound was obtained in analogy to example l (step B and C) using 3-chloro-<br>
2-methylbenzenesulfonyl chloride (step C) as an off-white solid. MS (ESI"1):<br>
409.1[M+Hf).<br>
Example 125:<br>
2,4-DichIoro-[l-(3,4-difluoro-benzyI)-2-methyl-3-oxo-23-dihydro-indazol-5-yl]-6-<br>
methyl-benzenesulfonamide<br>
Part A] l -(3,4-Difluoro-benzyl)-2-methyl-5 -nitro-1,2-dihydro-indazol-3 -one<br>
To a solution of l-(3,4-difluoro-benzyl)-5-nitro-l,2-dihydro-indazol-3-one (prepared<br>
in analogy to example 80 using 3,4-difluorobenzylbromide (step A)) (0.2 g) in DMF<br>
was added NaH (0.019 g) and the solution was stirred for l hour. lodomethane (0.14<br>
g) was then added and the mixture was stirred overnight. The reaction mixture was<br>
quenched with water and extracted with EtOAc. The combined organic layers were<br>
washed with brine, dried over sodium sulfate, filtered and evaporated in vacuo to<br>
afford a crude orange residue. Flash column chromatography of the crude residue over<br>
silica gel afforded the desired l-(3,4-difluoro-benzyl)-2-methyl-5-nitro-l,2-dihydroindazol-<br>
3-one (0.11 g) as a yellow solid. MS (ESI'): 318.1 ([M-H]').<br>
Part B] 12,4-Dichloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2,3-dihydroindazol-<br>
5-yl]-6-methyl-benzenesulfonamide<br>
This; compound was obtained in analogy to example l (step B and C) using 2,4-<br>
dichloro-6-methylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI"1):<br>
534.2 [M+Na]+).<br>
Example 126:<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2-dihydro-indazol-5-yl]-2-<br>
methyl-benzenesulfonamide<br>
This; compound was obtained in analogy to example 125 using 3-chloro-2-<br>
methylbenzenesulfonyl chloride (step C) as a white solid. MS (ESI~): 478.3 [M-H]").<br>
Example 127:<br>
2,3-Dichloro-N-(6-chloro-3-oxo-l-pyridin-2-yImethyl-2,3-dihydro-lH-indazol-5-<br>
yl)-benzenesulfonamide<br>
This compound was obtained in analogy to example 119 using 2-chloromethylpyridine<br>
(step A) and 2,3-dichlorobenzenesulfonyl chloride (step C) as a light brown<br>
solid MS (ESI): 482.9[M+H]+).<br>
Example 128:<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-difluorobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzpic<br>
acid, benzylhydrazine.2HCl (step A) and 2,4-difluorobenzenesulfonyl<br>
chloride (step C) as a light brown solid. MS (ESI): 434. l [M+Hf).<br>
Example 129:<br>
N-(6Chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-<br>
3-trifluoromethyl-benzenesulfonamide<br>
This compound was obtained in analogy to example 32 (step B and C) using 5-nitrol-<br>
phenyl-l,2-dihydro-indazol-3-one (prepared according to Combinatoriul Chemistry<br>
and High Throughput Screening 2003, 6(5), 471-480) in step B and 2,4-<br>
difluorobenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI4):<br>
402.3 [M+H]+).<br>
Example 130:<br>
N-(6ChIoro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-<br>
3-trifIuoromethyl-benzenesuIfonamide<br>
This compound was obtained in analogy to example 32 (step B and C) using 5-nitrol-<br>
phenyl-l,2-dihydro-indazol-3-one (prepared according to Combinatoria! Chemistry<br>
and High Throughput Screening 2003, 6(5), 471-480) in step B and and 3-chloro-<br>
fluorbbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI1):<br>
418.2[M+H]+).<br>
Example 131:<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazoI-5-yI)-3-cyanobenzenesulfonamide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 3-cyanobenzenesulfonyl chloride<br>
(step; C) as a light brown solid. MS (ESI+'): 423.0[M+H]+).<br>
Example 132:<br>
Propane-2-sulfonic acid (l-beiizyI-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-<br>
amide<br>
This compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and 3 propane-2-sulfonyl chloride (step<br>
C) as a light brown solid. MS (ESf): 364. l [M+H]+).<br>
Example 133:<br>
3-Cyano-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide<br>
This Icompound was obtained in analogy to example 32 (step B and C) using 5-nitrol-<br>
phenyl-l,2-dihydro-indazol-3-one (prepared according to Combinatorial Chemisîry<br>
and High Throughput Screening 2003, 6(5), 471-480) in step B and and 3-<br>
cyanpbenzenesulfonyl chloride (step C) as a light brown solid. MS (ESI"1):<br>
391.1[M+Hf).<br>
Example 134:<br>
2,2,2-Trifluoro-ethanesulfonic acid (l-benzyl-6-fluoro-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl)-amide<br>
This; compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzbic<br>
acid, benzylhydrazine.2HCl (step A) 2,2,2-trifluoro-ethanesulfonyl chloride<br>
(step; C) as a light brown solid. MS (ESf): 404.1[M+H]+).<br>
Example 135:<br>
Propane-2-suIfonic acid (l-benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazoI-5-yl)-<br>
amide<br>
This i compound was obtained in analogy to example 32 using 4-chloro-2-fluoro-5-<br>
nitro-benzoic acid, benzylhydrazine.2HCl (step A) and 3 propane-2-sulfonyl chloride<br>
(stepi C) as a light beige solid. MS (ESf): 380. l [M+H]+).<br>
Example 136:<br>
Propane-2-sulfonic acid [6-chloro-l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lHindazol-<br>
5-yl]-amide<br>
This compound was obtained in analogy to example 1 19 using 4-chlorobenzylbromide<br>
and 5-amino-6-chloro-l-(2-chloro-benzyl)-l,2-dihydro-indazol-3-one (step A) and 3<br>
propane-2-sulfonyl chloride (step C) as a light brown solid. MS (ESI1"): 414.3<br>
Example 137:<br>
N-(l-Benzyl-6-fluoro-3-oxo-2-dihydro-lH-indazol-5-yl)-trifluoromethanesulfonamide<br>
This ; compound was obtained in analogy to example 32 using 2,4-difluoro-5-nitrobenzoic<br>
acid, benzylhydrazine.2HCl (step A) and trifluoro-methanesulfonyl chloride<br>
(step; C) as a light brown solid. MS (ESf): 390. l [M+Hf).<br>
Example 138:<br>
Propane-2-sulfonic acid (l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide<br>
This -compound was obtained in analogy to example 32 using 5-amino-l-isobutyl-l,2-<br>
dihydro-indazol-3-one and 3 propane-2-sulfonyl chloride (step G) as a beige solid. MS<br>
(ESrb:312.1[M+H]+).<br>
Example 139:<br>
Propane-2-sulfonic acid [l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-<br>
yl]-amide<br>
This compound was obtained in analogy to example 80 using 3,4-<br>
difluorobenzylbromide (step A) and 3 propane-2-sulfonyl chloride (step C) as a light<br>
yellow solid. MS (ESI): 382.3 [M+H]).<br>
Example 140:<br>
Propane-2-sulfonic acid [l-(2-methoxy-ethyI)-3-oxo-2,3-dihydro-lH-indazol-5-<br>
yl]-amide<br>
This compound was obtained in analogy to example 32 using (2-methoxy-ethyl)-<br>
hydrazine (step A) (prepared as described in J. Org. Chem. 1984, 49, 336-42) and 3<br>
propâne-2-sulfonyl chloride (step C) as a light brown solid. MS (ESI): 314.0<br>
[M+Hft.<br>
Example 141:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-C-cyclopropylmethanesulfonamide<br>
This i compound was obtained in analogy to example l using 5-amino-l-benzyl-l,2-<br>
dihydro-indazol-3-one and cyclopropyl-methanesulfonyl chloride (step C) as a light<br>
brown solid. MS (ESf): 358.4 ([M+Hf).<br>
Example A<br>
Film coated tablets containing the following ingredients can be manufactured in<br>
a convenţional manner:<br>
Ingredients<br>
: Per tabiet<br>
Kernel:<br>
Compound of formula (I) 10.0 mg 200.0 mg<br>
Microcrystalline cellulose 23.5 mg 43.5 mg<br>
Lactose hydrous 60.0 mg 70.0 mg<br>
PovidoneK30 12.5 mg 15.0 mg<br>
Sodium starch glycolate 12.5 mg 17.0 mg<br>
67<br>
Magnesium stearate 1.5 mg 4.5 mg<br>
(Kernel Weight) 120.0 mg 350.0 mg<br>
Film Coat:<br>
Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg<br>
Polyethylene glycol 6000 0.8 mg l .6 mg<br>
Talc 1.3 mg 2.6 mg<br>
Iron oxyde (yellow) 0.8 mg 1.6 mg<br>
Titan dioxide 0.8 mg l .6 mg<br>
The active ingredient is sieved and mixed with microcristalline cellulose and the<br>
mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is<br>
mixed with sodium starch glycolate and magesiumstearate and compressed to yield<br>
kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous<br>
solution / suspension of the above mentioned film coat.<br>
Example B<br>
Capsules containing the following ingredients can be manufactured in a<br>
convenţional manner:<br>
Ingredients Per capsule<br>
Compound of formula (I) 25.0 mg<br>
Lactose 150.0 mg<br>
Maize starch 20.0 mg<br>
Talc 5.0 mg<br>
The eomponents are sieved and mixed and filled into capsules of size 2.<br>
Example C<br>
Injection solutions can have the following composition:<br>
Compound of formula (I) 3.0 mg<br>
Polyethylene Glycol 400 150.0 mg<br>
Acetic Acid q.s. adpHS.O<br>
Water for injection solutions ad l .0 ml<br>
The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and<br>
watef for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is<br>
adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered,<br>
filled into vials using an appropriate overage and sterilized.<br>
69<br>
Example D<br>
Soft gelatin capsules containing the following ingredients can be manufactured<br>
in a convenţional manner:<br>
Capsule contents<br>
Compound of formula (I) 5.0 mg<br>
Yellow wax 8.0 mg<br>
Hydrogenated Soya bean oii 8.0 mg<br>
Partially hydrogenated plant oils 34.0 mg<br>
Soya bean oii 110.0 mg<br>
Weight of capsule contents 165.0 mg<br>
Gelatin capsule<br>
Gelatin 75.0 mg<br>
Glycerol 85 % 32.0 mg<br>
Karibn 83 8.0 mg (dry matter)<br>
Titan dioxide 0.4 mg<br>
Iron oxide yellow l. l mg<br>
The active ingredient is dissolved in a warm melting of the other ingredients and<br>
the mixture is filled into soft gelatin capsules of appropriate size. The filled soft<br>
gelatin capsules are treated according to the usual procedures.<br>
Example E<br>
Sachets containing the following ingredients can be manufactured in a<br>
convenţional manner:<br>
Compound of formula (I) 50.0 mg<br>
Lactose, fine powder 1015.0 mg<br>
Microcristalline cellulose (AVICEL PH 102) 1400.0 mg<br>
Sodium carboxymethyl cellulose 14.0 mg<br>
Polyvinylpyrrolidon K 30 10.0 mg<br>
Magnesiumstearate 10.0 mg<br>
Flavoring additives 1.0 mg<br>
The active ingredient is mixed with lactose, microcristalline cellulose and<br>
sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon<br>
in water. The granulate is mixed with magnesiumstearate and the flavouring additives<br>
and fii led into sachets.<br><br><br><br>
We Claim:<br>
1.	Compounds of formula (I)<br>
(Formula Removed)<br>
wherein<br>
R1 is hydrogen, C1-C7-alkyl, aryl, or aryl-C1-C7-alkyl;<br>
R2 is aryl, aryl-C1-C7-alkyl, heteroaryl, heteroaryl-C1-C7-alkyl, cycloalkyl, cycloalkyl-<br>
C1-C7-alkyl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is optionally<br>
substituted with 1 to 3 substituents selected from the group consisting of OH, CN,<br>
halogen, C1-C7-alkoxy and C(O)NR8R9;<br>
R3 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R4 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fiuoro-C1-<br>
C7-alkoxy;<br>
R5 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R6 is hydrogen or C1-C7-alkyl;<br>
R7 is aryl, heteroaryl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is<br>
optionally substituted with 1 to 3 substituents selected from the group consisting of OH,<br>
CN, halogen, C1-C7-alkoxy and cycloalkyl;<br>
R8 and R9 , independently from each other, are selected from the group consisting of hydrogen and C1-C7-alkyl;<br>
and pharmaceutically acceptable salts thereof.<br>
2.	The compounds as claimed in claim 1, wherein<br>
R1 is hydrogen, C1-C7-alkyl, aryl, or aryl-C1-C7-alkyl;<br>
R2 is aryl, aryl-C1-C7-alkyl, heteroaryl, heteroaryl-C1-C7-alkyl, cycloalkyl, cycloalkyl-<br>
C1-C7-alkyl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is optionally<br>
substituted with 1 to 3 substituents selected from the group consisting of OH, CN,<br>
halogen, C1-C7-alkoxy and C(O)NR8R9;<br>
R3 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R4 is hydrogen, halogen, C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R5 is hydrogen, halogen, C1-C7-alkyl, fiuoro-C1-C7-alkyl, C1-C7-alkoxy, or fluoro-C1-<br>
C7-alkoxy;<br>
R6 is hydrogen or C1-C7-alkyl;<br>
R7 is aryl, heteroaryl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is<br>
optionally substituted with 1 to 3 substituents selected from the group consisting of OH,<br>
CN, halogen and C1-C7-alkoxy;<br>
R8 and R9, independently from each other, are selected from the group consisting of<br>
hydrogen and C1-C7-alkyl;<br>
and pharmaceutically acceptable salts thereof.<br>
3.	The compounds as claimed in any of claims 1 to 2, wherein R1 is hydrogen or C1-C7-alkyl.<br>
4.	The compounds as claimed in any of claims 1 to 3, wherein R1 is hydrogen.<br>
5.	The compounds as claimed in any of claims 1 to 4, wherein R2 is aryl-C1-C7-alkyl, heteroaryl-C1-C7-alkyl, cycloalkyl-C1-C7-alkyl, fluoro-C1-C7-alkyl, or C1-C7-alkyl, which C1-C7-alkyl is optionally substituted with 1 to 3 substituents selected from the group consisting of OH, CN, halogen, C1-C7-alkoxy and C(O)NR8R9, wherein R8 and R9 are as defined in claim 1.<br>
6.	The compounds as claimed in any of claims 1 to 5, wherein R2 is aryl-C1-C7-alkyl or heteroaryl-C1-C7-alkyl.<br>
7.	The compounds as claimed in any of claims 1 to 6, wherein R2 is benzyl or pyridinylmethyl, wherein benzyl can optionally be substituted with 1 or 2 halogen.<br>
8.	The compounds as claimed in any of claims 1 to 7, wherein R2 is benzyl, 4-fluoro-benzyl, 4-chloro-benzyl, 3,4-difiuoro-benzyl, or pyridin-2-ylmethyl.<br>
9.	The compounds as claimed in any of claims 1 to 4, wherein R2 is aryl.<br>
10.	The compounds as claimed in any of claims 1 to 9, wherein R3 is hydrogen.<br>
11.	The compounds as claimed in any of claims 1 to 10, wherein R4 is hydrogen or halogen.<br>
12.	The compounds as claimed in any of claims 1 to 11, wherein R4 is hydrogen, fluorine, or chlorine.<br>
13.	The compounds as claimed in any of claims 1 to 12, wherein R5 is hydrogen or halogen.<br>
14.	The compounds as claimed in any of claims 1 to 13, wherein R5 is hydrogen.<br>
15.	The compounds as claimed in any of claims 1 to 14, wherein R6 is hydrogen.<br>
16.	The compounds as claimed in any of claims 1 to 15, wherein R7 is C1-C7-alkyl or aryl.<br>
17.	The compounds as claimed in any of claims 1 to 16, wherein R7 is C1-C7-alkyl, phenyl or naphthyl, wherein phenyl can optionally be substituted with 1 to 3 substituents independently selected from the group consisting of C1-C7-alkyl, fluoro-C1-C7-alkyl, C1-C7-alkoxy, fluoro-C1-C7-alkoxy, dioxo-C1-C7-alkylene, halogen, cyano, phenoxy and 5-methyl-[l,3,4]-oxadiazol-2-yl.<br>
18.	The compounds as claimed in any one of claims 1 to 17, wherein R7 is phenyl substituted with 1 to 2 substituents selected from the group consisting of C1-C7-alkyl, fluoro-C1-C7-alkyl, halogen and cyano.<br>
19.	The compounds as claimed in claim 18, wherein R7 is 3-chloro-2-methyl-phenyl, 2,3-dichloro-phenyl, 3-chloro-4-fluoro-phenyl, 3-trifluoromethyl-4-fluoro-phenyl, 3-cyano-phenyl, 2,5-difluoro-phenyl, 3-chloro-2-fluoro-phenyl, 5-chloro-2-fluoro-phenyl, or 2-chloro-phenyl.<br>
20.	The compounds as claimed in any of claims 1 to 15, wherein R7 is fluoro-C1-C7-alkyl or C1-C7-alkyl substituted with cyclopropyl.<br>
21.	The compounds as claimed in claim 20, wherein R7 is cyclopropyl-methyl.<br>
22.	The compounds as claimed in any of claims 1 to 21 selected from the group consisting of:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methyl-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-fluoro-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-benzenesulfonamide,<br>
Naphthalene-2-sulfonicacid(l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-4-methyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-1H-indazol-5-yl)-4-methoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-6-methyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-difluoro-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-propyl-benzenesulfonamide,<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonic acid(l-benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-2,5-dimethyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-3-trifluoromethyl-benzenesulfonamide,<br>
N-(1-Benzyl-3 -oxo-2,3 -dihydro-1H-indazol-5-yl)-4-fluoro-3 -trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chloro-5-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-phenoxy-benzenesulfonamide,<br>
N-(l -Benzyl-3-oxo-2,3-dihydro-1H-indazol-5-yl)-3-(5-methyl-[ 1,3,4]oxadiazol-2-yl)-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-methoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-difluoromethoxy-benzenesulfonamide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3,5-bis-trifluoromethyl-benzenesulfonamide,<br>
Propane-2-sulfonic acid (1 -benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-amide,<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-N-dimethyl-benzenesulfonamide,<br>
N-(3-Oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethyl-benzenesulfonamide,<br>
2,3-Dichloro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-4-fluoro-N-(3-oxo-l-propyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-2-methyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-4-methyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
4-Chloro-2,5-dimethyl-N-(3-oxo-l-phenethyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
N-(3 -Oxo-1 -phenethyl-2,3 -dihydro-1H-indazol-5-yl)-3 -trifluoromethyl-benzenesulfonamide,<br>
N-(l -Isobutyl-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-trifluoromethyl-benzenesxilfonamide,<br>
3 -Chloro-N-( 1 -isobutyl-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl)-4-methyl-benzenesulfonamide,<br>
3-Chloro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-methyl-benzenesulfonamide,<br>
3-Cyano-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
3-Difluoromethoxy-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
4-Cyano-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
4-Fluoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-4-fluoro-N-(l-isobutyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
2,4-Dichloro-(l-isobutyl-3-oxo-2,3-dihydro-indazol-5-yl)-5-methyl-benzenesulfonamide,<br>
3-Chloro-N-(l-ethyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-methyl-benzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-2-methyl-benzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluoro-benzenesulfonamide,<br>
(l-Cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-benzenesulfonamide,<br>
2,4-Dichloro-(l-cyclopropylmethyl-3-oxo-2,3-dihydro-indazol-5-yl)-5-methyl-benzenesulfonamide,<br>
3-Chloro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
4-Fluoro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-3-trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-4-fluoro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
2,4-Dichloro-[l-(2-methoxy-ethyl)-3-oxo-2,3-dihydro-indazol-5-yl]-6-methyl-benzenesulfonamide,<br>
3-Chloro-2-methyl-N-[3-oxo-l-(2,2,2-trifluoro-ethyl)-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
4-Fluoro-[3-oxo-l-(2,2,2-trifluoro-ethyl)-2,3-dihydro-indazol-5-yl]-3-trifluoromethyl-<br>
benzenesulfonamide,<br>
4-Fluoro-N-(3 -oxo-1 -pyridin-2-ylmethyl-2,3 -dihydro-1 H-indazol-5-yl)-3 -trifluoromethyl-benzenesulfonamide,<br>
2,4-Dichloro-6-methyl-N-(3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3-Chloro-2-methyl-N-(3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
4-Fluoro-N-[l-(2-hydroxy-2-methyl-propyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-trifluoromethyl-benzenesulfonamide,<br>
N-( 1 -Benzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-chloro-4-fluoro-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-methyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichloro-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-cyano-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-chloro-3-trifluoromethyl-benzenesulfonamide,<br>
N-( 1 -Benzyl-6-chloro-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl)-3 -difluoromethoxy-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-trifluoromethoxy-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,5-difluoro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluoro-benzenesulfonamide,<br>
N-( 1 -Benzyl-6-chloro-3 -oxo-2,3 -dihydro-1 H-indazol-5 -yl)-3 -trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-5-chloro-2-fluoro-benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2-chloro-benzenesulfonamide,<br>
(l-Benzyl-4-chloro-3-oxo-2,3-dihydro-indazol-5-yl)-3-chloro-2-methyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichloro-benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,4-dichloro-benzenesulfonamide,<br>
N-(l -Benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-chloro-2-fluoro-benzenesulfonamide,<br>
N-( 1 -Benzyl-6-fluoro-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl)-5-chloro-2-fluoro-benzenesulfonamide,<br>
N-(l -Benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-trifluoromethoxy-benzenesulfonamide,<br>
3-Chloro-N-[ 1 -(4-fluoro-benzyl)-3-oxo-2,3-dihydro-l H-indazol-5-yl]-benzenesulfonamide,<br>
3-Difluoromethoxy-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
4-Fluoro-N-[ 1 -(4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-3-trifluoromethyl-<br>
benzenesulfonamide,<br>
2,3-Dihydro-benzo[l,4]dioxine-6-sulfonicacid [l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-amide,<br>
2,4-Dichloro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-6-methyl-benzenesulfonamide,<br>
5-Chloro-2,4-difluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
4-Chloro-2,5-difluoro-N-[ 1 -(4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-benzenesulfonamide,<br>
3-Chloro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
3-Cyano-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
Naphthalene-1 -sulfonic acid [ 1 -(4-fluoro-benzyl)-3-oxo-2,3-dihydro-l H-indazol-5-yl]-amide,<br>
3-Chloro-4-fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluoro-benzenesulfonamide,<br>
[l-(3,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difiuoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
[l-(3,4-Difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-3-trifluoromethoxy-benzenesulfonamide,<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-5-methyl-benzenesulfonamide,<br>
3,4-Dichloro-[ 1 -(3,4-difluoro-benzyl)-3 -oxo-2,3 -dihydro-indazol-5-yl] -benzenesulfonamide,<br>
4,5-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-fluoro-benzenesulfonamide,<br>
2,4,5-Trichloro-[ 1 -(3,4-difiuoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
2,3-Dichloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
2,4-Dichloro-[l-(3,4-difiuoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-6-methyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-benzenesulfonamide,<br>
N- [ 1 -(2,4-Difluoro-benzyl)-3 -oxo-2,3 -dihydro-1 H-indazol-5 -yl]-4-fluoro-3 -trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(2,4-difluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
2,3-Dichloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
Naphthalene-1 -sulfonic acid [ 1 -(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-amide,<br>
3-Chloro-N-[l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
Naphthalene-1 -sulfonic acid [ 1 -(2-chloro-4-fluoro-benzyl)-3 -oxo-2,3 -dihydro-1H-indazol-5-yl]-amide,<br>
2,3-Dichloro-N-[l-(2-chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifiuoromethyl-benzenesulfonamide,<br>
N-[ 1 -(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-3-difluoromethoxy-benzenesulfonamide,<br>
N-[l-(2-Chloro-4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-3-trifluoromethoxy-benzenesulfonamide,<br>
3-Chloro-N-[ 1 -(2-cyano-ethyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
N-[l-(2-Cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
2,4-Dichloro-N-[ 1 -(2-cyano-ethyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-6-methyl-benzenesulfonamide,<br>
3-Chloro-N-[l-(2-cyano-ethyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-benzenesulfonamide,<br>
N-[6-Chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
5-Chloro-N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-2-fluoro-benzenesulfonamide,<br>
2,3-Dichloro-N-[6-chloro-l-(2-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-benzenesulfonamide,<br>
3-Chloro-N-(6-chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-2-methyl-benzenesulfonamide,<br>
N-(6-Chloro-3-oxo-l-pyridin-2-ylmethyl-2,3-dihydro-lH-indazol-5-yl)-4-fluoro-3-trifluoromethyl-benzenesulfonamide,<br>
2-[5-(3-Chloro-2-methyl-benzenesulfonylamino)-3-oxo-2,3-dihydro-indazol-l-yl]-methyl-acetamide,<br>
2,4-Dichloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2,3-dihydro-indazol-5-yl]-6-methyl-benzenesulfonamide, and<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-2-methyl-3-oxo-2,3-dihydro-indazol-5-yl]-2-methyl-benzenesulfonamide,<br>
and pharmaceutically acceptable salts thereof.<br>
23. The compounds as claimed in any one of claims 1 to 22 selected from the group<br>
consisting of:<br>
N-( 1 -Benzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-3-chloro-2-methyl-<br>
benzenesulfonamide,<br>
N-( 1-Benzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-2,5-difluoro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-chloro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluoro-<br>
benzenesulfonamide,<br>
N-( 1 -Benzyl-6-chloro-3 -oxo-2,3-dihydro-1 H-indazol-5-yl)-2-chloro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-chloro-2-fluoro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-2,3-dichloro-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fiuoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-5-chloro-2-fluoro-<br>
benzenesulfonamide,<br>
N-( 1 -Benzyl-3 -oxo-2,3 -dihydro-1 H-indazol-5 -yl)-3 -chloro-2-methyl-<br>
benzenesulfonamide,<br>
3-Cyano-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-benzenesulfonamide,<br>
2,3-Dichloro-N-[l-(4-chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
3-Chloro-N-[ 1 -(4-chloro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-2-methyl-<br>
benzenesulfonamide,<br>
4-Fluoro-N-[ 1 -(4-fluoro-benzyl)-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl] -3 -trifluoromethyl-<br>
benzenesulfonamide,<br>
3-Chloro-4-fluoro-N-[l-(4-fluoro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-<br>
benzenesulfonamide,<br>
3-Chloro-[l-(3,4-difluoro-benzyl)-3-oxo-2,3-dihydro-indazol-5-yl]-2-methyl-<br>
benzenesulfonamide,<br>
N-[l-(4-Chloro-benzyl)-3-oxo-2,3-dihydro-lH-indazol-5-yl]-4-fluoro-3-trifiuoroniethyl-<br>
benzenesulfonamide, and<br>
3 -Chloro-2-methyl-N-(3 -oxo-1 -pyridin-2-ylmethyl-2,3 -dihydro-1 H-indazol-5-yl)-<br>
benzenesulfonamide,<br>
and pharmaceutically acceptable salts thereof.<br>
24. The compounds as claimed in any one of claims 1 to 21 selected from the group<br>
consisting of:<br>
2,3-Dichloro-N-(6-chloro-3 -oxo-1 -pyridin-2-ylmethyl-2,3 -dihydro-1 H-indazol-5-yl)-<br>
benzenesulfonamide,<br>
N-( 1 -Benzyl-6-fluoro-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl)-2,4-difiuoro-<br>
benzenesulfonamide,<br>
2,4-Difluoro-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
3 -Chloro-2-fluoro-N-(3 -oxo-1 -phenyl-2,3 -dihydro-1 H-indazol-5-yl)-<br>
benzenesulfonamide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-3-cyano-benzenesulfonamide,<br>
Propane-2-sulfonic acid (1 -benzyl-6-fluoro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-amide,<br>
3-Cyano-N-(3-oxo-l-phenyl-2,3-dihydro-lH-indazol-5-yl)-benzenesulfonamide,<br>
2,2,2-Trifluoro-ethanesulfonic acid (1 -benzyl-6-fiuoro-3 -oxo-2,3 -dihydro-1 H-indazol-5-<br>
yl)-amide,<br>
Propane-2-sulfonic acid (1 -benzyl-6-chloro-3-oxo-2,3-dihydro-1 H-indazol-5-yl)-amide,<br>
Propane-2-sulfonic acid [6-chloro-1 -(4-chloro-benzyl)-3-oxo-2,3-dihydro-1 H-indazol-5-<br>
yl]-amide,<br>
N-(l-Benzyl-6-fluoro-3-oxo-2,3-dihydro-lH-indazol-5-yl)-trifluoro-<br>
methanesulfonamide,<br>
Propane-2-sulfonic acid (1 -isobutyl-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl)-amide,<br>
Propane-2-sulfonic acid [ 1 -(3,4-difluoro-benzyl)-3 -oxo-2,3 -dihydro-1 H-indazol-5-yl] -<br>
amide,<br>
Propane-2-sulfonic acid [ 1 -(2-methoxy-ethyl)-3-oxo-2,3-dihydro-1 H-indazol-5-yl]-<br>
amide, and<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-C-cyclopropyl-methanesulfonamide<br>
and pharmaceutically acceptable salts thereof.<br>
25.	The compound as claimed in any one of claims 1 to 21 which is:<br>
N-(l-Benzyl-3-oxo-2,3-dihydro-lH-indazol-5-yl)-C-cyclopropyl-methanesulfonamide<br>
and pharmaceutically acceptable salts thereof.<br>
26.	A process for the preparation of compounds as claimed in any of claims 1 to 25<br>
comprising the reaction of a compound of formula (II)<br>
(Formula Removed)<br>
with a compound of formula (III)<br>
(Formula Removed)<br>
wherein R1 to R7 are as defined in any of claims 1 to 25.<br>
27.	The compounds as claimed in any of claims 1 to 25 for use as therapeutic active substances for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are caused by disorders associated with the enzyme 1 lbeta-hydroxysteroid dehydrogenase 1, such as metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1ERUxOUC0yMDA3LUFic3RyYWN0LSgwNi0wMy0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">2319-DELNP-2007-Abstract-(06-03-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWFzc2lnbm1lbnQucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1ERUxOUC0yMDA3LUNsYWltcy0oMDYtMDMtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">2319-DELNP-2007-Claims-(06-03-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1ERUxOUC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMDYtMDMtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">2319-DELNP-2007-Correspondence Others-(06-03-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWNvcnJlc3BvbmRlbmNlLW90aGVycy0xLnBkZg==" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-correspondence-others-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1ERUxOUC0yMDA3LURlc2NyaXB0aW9uIChDb21wbGV0ZSktKDA2LTAzLTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">2319-DELNP-2007-Description (Complete)-(06-03-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1ERUxOUC0yMDA3LUZvcm0tMy0oMDYtMDMtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">2319-DELNP-2007-Form-3-(06-03-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LXBjdC0zMDQucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-pct-304.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMxOS1kZWxucC0yMDA3LXBjdC00MDkucGRm" target="_blank" style="word-wrap:break-word;">2319-delnp-2007-pct-409.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="252370-a-process-for-the-production-of-a-dihydronepetalactone.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="252372-a-computer-implemented-method-for-modelling-the-phase-conversion-of-a-steel-volume-with-a-volumetric-surface-in-a-cooling-down-process.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>252371</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2319/DELNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>19/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>11-May-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>10-May-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>26-Mar-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>H.HOFFMANN-LA ROCHE AG</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>GRENZACHERSTRASSE 124, CH-4070 BASEL (CH)</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CAI, JIANPING</td>
											<td>99 PARK STREET, WEST CALDWELL, NJ 07006, USA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KUHN, BERND</td>
											<td>SONNMATTWEG 42, CH-4410 LIESTAL, SWITZERLAND</td>
										</tr>
										<tr>
											<td>3</td>
											<td>NEIDHART, WERNER</td>
											<td>9, RUE DU STEINER, F-68220 HAGENTHAL LE BAS, FRANCE</td>
										</tr>
										<tr>
											<td>4</td>
											<td>GOODNOW, ROBERT, ALAN, JR</td>
											<td>799 LONG HILL ROAD, MORRIS COUNTY, GILLETTE, NJ 07933, USA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>HUNZIKER, DANIEL</td>
											<td>BUERKLISTRASSE 14, CH-4313 MOEHLIN, SWITZERLAND</td>
										</tr>
										<tr>
											<td>6</td>
											<td>MAYWEG, ALEXANDER</td>
											<td>MARTINSGASSE 8, CH-4051 BASEL, SWITZERLAND</td>
										</tr>
										<tr>
											<td>7</td>
											<td>AMREIN, KURT</td>
											<td>LETTENWEG 8, CH-4452 ITINGEN, SWITZERLAND</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 231/56</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2005/010175</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-09-21</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>04104753.1</td>
									<td>2004-09-29</td>
								    <td>EUROPEAN UNION</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/252371-indozolone-derivatives-as-11b-hsd-1-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:24:02 GMT -->
</html>
